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Introduction and Aims 
HIV and pre-eclampsia are the leading causes of maternal morbidity and mortality in South 
Africa. Despite active research, the pathophysiology of pre-eclampsia is not fully understood. 
The role of peripheral NK cells in pre-eclampsia is limited. Also, the effect of HIV on peripheral 
NK cells in pre-eclampsia is not well documented. Additionally a dysregulation of Th1 and Th2 
cytokine response is also known to occur both in pre-eclampsia and HIV. This novel study thus 
attempts to elucidate the role of peripheral NK cells and the Th1 and Th2 maternal immune 
response in HIV associated pre-eclampsia. The correlation of NK cells and their receptors with a 
panel of Th1 and Th2 cytokines were also determined.   
 
Methods 
Following institutional ethical approval and written informed consent, blood samples were 
obtained from 101 normotensive pregnant (51 HIV positive and 50 HIV negative), 81 early onset 
pre-eclamptic (EOPE; 37 HIV positive and 44 HIV negative) and 73 late-onset pre-eclamptic 
(LOPE; 29 HIV positive and 44 HIV negative) Black South Africans (>18 years) at Prince 
Mshiyeni Memorial Hospital, KwaZulu-Natal a regional hospital, in Durban, South Africa. 
These patients were either recruited directly on admission to the hospital or from the ante-natal 





Peripheral NK cell markers (CD3- BD Horizon 500, CD56dim PECy7 and CD16+ FITC) and their 
receptor expression (CD69 Brilliant VioletTM 421, CD94 PerCP-Cy5, NKG2A Alexa Fluor® 500, 
NKG2C PE and NKG2D APC) were analysed on the BDLSRFortessaTM flow cytometer and the 
data further analysed using FloJo V10. Th1 (IL-2, IL-12(p70), IFN-ƴ, TNF-α and GM-CSF) and 
Th2 (IL-4, IL-5, IL-10 and IL-13) maternal serum cytokine levels were determined using the 
Bio-Plex Pro™ Human Cytokine Th1/Th2 9-plex panel. Cytokine concentrations (pg/ml) were 
obtained with the Bio-Plex®MAGPIXTM Multiplex Reader. SPSS Statistics Version 23 was used 
to analyze the clinical and experimental data. Differences of p<0.05 were considered statistically 
significant.  
 
Results and Discussion 
This novel study found that peripheral NK (CD56dimCD16+) cells were significantly higher in the 
HIV negative (mean rank=114.41) compared to HIV positive group (mean rank=95.13; 
p=0.021). This is surprising as peripheral NK cells possess more cytotoxic properties and would 
be expected to be present in larger amounts in the HIV positive compared to the negative group. 
However, HIV infection is known to suppress the cytotoxic properties of NK cells which may 
explain these results. Pre-eclampsia is associated with exaggerated inflammation and increased 
production of cytokines (Schumacher, 2014). This study confirms this as increased accumulation 
of peripheral NK cells were observed in pre-eclamptic compared to the normotensive 
pregnancies (p=0.012). 
 
There were no significant differences in maternal serum Th1 and Th2 between the HIV positive 
and negative groups, pregnancy groups (normotensive, EOPE and LOPE) and across all six 
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study groups. In HIV associated pre-eclampsia there could be a counteraction in the Th1 and Th2 
cytokine levels hence a neutralization of Th1 and Th2 response.  
 
Conclusion 
To our knowledge, the quantification of peripheral NK cells as well as Th1 and Th2 maternal 
serum cytokines in HIV associated pre-eclampsia is novel. Our study supports the hypothesis 
that the levels of peripheral NK cells are higher in the HIV positive pre-eclamptic group 
compared to the HIV positive normotensive group. Our study also suggests a neutralisation 








1.1 MATERNAL MORTALITY  
In the last decade, global maternal mortality declined by 47%. The Millennium Development 
Goal 5 which recommended a 75% reduction in maternal death by 2015 has not been attained 
(Oyston et al., 2014; Burton, 2013). However, the World Health Organisation (WHO) estimates 
800 maternal deaths per day or 210 maternal deaths per 100 000 live births. These pregnancy-
related deaths are attributed to haemorrhage (35%), pre-eclampsia/eclampsia (18%), sepsis (8%), 
unsafe abortion (9%) and indirect causes including AIDS and malaria (18%) (Oyston et al., 
2014). Notably, resource poor countries account for 99% of maternal deaths with 85% occurring 
in Sub-Saharan Africa and Southern Asia (Oyston et al., 2014).  
 
In contrast, the three major causes of maternal deaths in South Africa are non-pregnancy related 
infections (35.8%, mostly HIV-related), obstetric haemorrhage (15.8%) and hypertensive 
disorders of pregnancy (14.8%) (Department of Health, Saving Mothers Reported, 2015). About 
54.2% of maternal deaths from hypertensive disorders of pregnancy are due to pre-eclampsia 
(Department of Health, Savings Mothers Reported, 2015). Furthermore, KwaZulu-Natal 
accounts for the highest maternal deaths (22%) compared to the other provinces in South Africa 
with 42.5% due to non-pregnancy related infections (NPRI), mostly HIV-related and 8.3% to 





Figure 1.1: Distribution of maternal deaths per province in South Africa, 2011-2013. KwaZulu-
Natal accounts for the highest maternal deaths (22%) compared to the other provinces in South 
Africa with 42.5% due to NPRI and 8.3% to pre-eclampsia (Department of Health, Saving 
Mothers Reported, 2015). 
 
According to the Ninth Interim Saving Mothers Reported there has been a significant reduction 
in maternal deaths from NPRI (mostly HIV-related), however deaths due to obstetric 
haemorrhage and hypertensive disorders of pregnancy still remain high (Department of Health, 
Saving Mothers Reported, 2015). The reduction in maternal deaths due to complications of HIV 
infection is largely due to antiretroviral therapy. Maternal deaths from obstetric haemorrhage and 
hypertensive disorders of pregnancy may be due to the lack of skills in performing assisted 
delivery and/or caesarean section and the lack of knowledge in predicting pre-
eclampsia/eclampsia in rural communities. Once diagnosed, poor infrastructure, lack of 
transport, poor road access and distance from rural areas to healthcare facilities place the mother 



































resourced healthcare facilities will aid in ameliorating these deaths (Pattinson, 2013; Oyston et 
al., 2014). Exacerbating this data is the fact that most pregnant women in developing countries 
present late for antenatal care and some never do seek postpartum care and follow-up. Therefore, 
education on the risks/dangers associated with pregnancy-related complications that contribute to 
maternal deaths are urgently warranted (Oyston et al., 2014). 
 
1.2 NORMAL PLACENTATION  
In the first trimester of normal pregnancy, maternal spiral arteries undergo remodeling by 
invasive foetal cytotrophoblast cells. These cells migrate across two pathways, (1) the interstitial 
pathway where they cross the decidua into the myometrium and (2) the endovascular pathway 
where they migrate into the lumen of the spiral artery (Wang et al., 2009). In the decidua, 
extravillous trophoblast cells replace the endothelial cells of the spiral arterioles hence enabling 
its physiological conversion into a large bore conduit (Figure 1.2). This allows for the 
nourishment of the growing fetus (Wang et al., 2009; Bachmayer et al., 2006). In pathological 





Figure 1.2: Normal placental development. Foetal cytotrophoblast cells invade the maternal 
uterine wall and remodel the maternal vessels into high capacitance and low resistance vessels 
that provide access to maternal oxygen and nutrients for the placenta and growing fetus (Wang, 
Rana and Karumanchi, 2009). 
 
1.3 HYPERTENSIVE DISORDERS OF PREGNANCY 
In recent years the diagnosis, classification and management of hypertensive disorders of 
pregnancy have been up-dated. In view of these developments, the International Society for the 
Study of Hypertension in Pregnancy (ISSHP) has recently revised the classification of 
hypertensive disorders of pregnancy into four categories (Tranquilli et al., 2014): 
1. Chronic hypertension refers to high blood pressure before pregnancy or in the first trimester of 
pregnancy. 
2. Gestational hypertension refers to new onset high blood pressure after 20 weeks of gestation 
without any other symptoms which define pre-eclampsia. 
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3. Pre-eclampsia – de novo (defined in 1.4 below) or superimposed on chronic hypertension. 
Superimposed pre-eclampsia refers to the development of any other symptom of pre-eclampsia 
after 20 weeks of gestation including chronic hypertension.   
4. White coat hypertension refers to presentation of high blood pressure up to 160-170/110 
mmHg only in a clinical setting (Tranquilli et al., 2014).  
 
1.4 PRE-ECLAMPSIA 
Pre-eclampsia is characterized by new onset high blood pressure (>140/90 mmHg) and 
proteinuria (≥300 mg in a 24 h urine sample or a dipstick result of ≥1+) in pregnant women in 
the second half of pregnancy (Magee et al., 2014) or in the absence of proteinuria, the new onset 
of platelet count less than 100 000/µl called thrombocytopenia, serum creatinine concentrations 
greater than 1.1 mg/dL or a doubling of the serum creatinine concentration in the absence of 
other renal disease, impaired liver function, pulmonary oedema or cerebral or visual symptoms 
(Tranquilli et al., 2014; ACOG Practice Bulletin., 2002).  
 
Pre-eclampsia may progress to eclampsia which is characterized by new-onset of grand mal 
seizures and affects 2.7-8.2 women per 10 000 deliveries (Chaiworapongsa et al., 2014). In 
South Africa, 2% of maternal deaths are attributed to eclampsia (Department of Health, Saving 
Mothers Reported, 2012). Maternal outcomes from pre-eclampsia and eclampsia may include 
cerebrovascular accidents, liver rupture and pulmonary oedema or acute renal failure that can 
result in maternal deaths (Chaiworapongsaet et al., 2014). Perinatal outcomes include preterm 
delivery, intrauterine growth restriction and (IUGR) and foetal death as well as haematologic 
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effects and bronchopulmonary dysplasia (Backes et al., 2011). The only effective treatment of 
pre-eclampsia is delivery of the placenta (Naljayan and Karumanchi, 2013).  
 
1.4.1 Pre-eclampsia classification 
Pre-eclampsia can be classified as early (<34 weeks) or late (>34 weeks) onset (Tranquilli et al., 
2014). Early onset pre-eclampsia (EOPE) is uncommon with a prevalence of 0.3-12% of all pre-
eclampsia.  It is associated with extensive villous and vascular lesions of the placenta and has a 
higher risk of maternal and foetal complications than late onset pre-eclampsia (LOPE) 
(Chaiworapongsaet et al., 2014). LOPE has a prevalence of 2.72% or 88%, minimal placental 
lesions, maternal factors such as metabolic syndrome and hypertension and most cases of 
eclampsia and maternal deaths  (Wang et al., 2009; Lisonkova and Joseph 2013).  
 
1.5 PATHOGENESIS OF PRE-ECLAMPSIA 
The etiology and pathology of pre-eclampsia is not fully understood. This disease occurs only in 
pregnant women and remits after delivery of the placenta (Wang et al., 2009). The placenta is 
therefore a vital organ in understanding the pathogenesis of pre-eclampsia (Wang et al., 2009). A 
number of factors have been implicated in the pathogenesis of pre-eclampsia which elicit an 
exaggerated inflammatory response that results in defective placentation and consequential 
failure of the physiological transformation of maternal spiral arteries. These factors include 
abnormal foetal cytotrophoblast and decidual interaction, renin-angiotensin-aldosterone system 
II (increased AT1 autoantibodies), angiogenic and anti-angiogenic factors, immunological 
intolerance (genetic factors), placental oxidative stress and syncytiotrophoblast debris (Figure 
1.3, (Chaiworapongsa et al., 2014; Wang et al., 2009).  
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Figure 1.3: A model depicting the complex pathophysiology of pre-eclampsia. Genetic factors, 
oxidative stress, NK cell abnormalities and other factors result in growth restriction of the fetus. 
This leads to the release of antiangiogenic and angiogenic factors, as well as other inflammatory 
factors which induces pre-eclampsia and other diseases. (Adapted from Chaiworapongsa et al., 




1.5.1. Abnormal placentation in pre-eclampsia 
Pre-eclampsia occurs in two stages, placental and maternal. In the placental stage, the migration 
of invasive cytotrophoblast into the myometrium is deficient in the first trimester.  Physiological 
conversion of the spiral arteries is limited to the decidua and their luminal diameter within the 
myometrium is considerably reduced (Naicker et al., 2013; Walker, 2011). Blood flow to the 
placenta is reduced; hence nutrient and oxygen transfer across the placenta limits foetal growth 
(Figure 1.4).  
 
Furthermore, in the maternal stage after 20 weeks of gestation, trophoblast cell debris is released 
into the maternal circulation and induces an inflammatory response in the second trimester of 
pregnancy (Bachmayer et al., 2006).  Both the vasocontriction and the elevated inflammatory 
response contribute to the hypertension, oedema and proteinuria that characterises pre-eclampsia. 
The invading trophoblast, maternal immunological cells such as Natural Killer cells play an 




Figure 1.4: Abnormal placental development in pre-eclampsia. Depth of trophoblast invasion is 
less in pre-eclampsia compared to normal pregnancy which results in inadequate transformation 
of maternal spiral arteries. The blood flow to the feto-placental unit is reduced and this leads to 
poor foetal growth (Wang et al., 2009). 
 
1.5.2 Renin--angiotensin-aldosterone system  
The renin–angiotensin system (RAS) or the renin–angiotensin–aldosterone system (RAAS) is a 
hormone system responsible for regulating blood pressure, sodium and fluid balance (Uddin, 
2014). A reduced blood flow to the kidneys causes the juxtaglomerular cells to release the 
enzyme called renin which cleaves angiotensinogen, the only renin substrate, into angiotensin I. 
Angiotensin I is then converted to angiotensin II by angiotensin-converting enzyme (ACE). 
Angiotensin II binds to its receptors, AT1R and AT2R leading to vasoconstriction and the 




1.5.3 Anti-angiogenic and angiogenic factors 
Angiogenesis is the formation of new blood vessels which involves the migration, growth and 
differentiation of endothelial cells. Angiogenic growth factors are necessary for the formation of 
blood vessels. Pre-eclampsia is associated with an imbalance between anti-angiogenic and 
angiogenic factors. Anti-angiogenic factors such as soluble fms-like tyrosine kinase 1 (sFlt1) and 
soluble endoglin (sEng) are upregulated and angiogenic factors such as placental growth factor 
(PIGF) and vascular endothelial growth factor (VEGF) are downregulated which result in 
disruption of the maternal endothelium and ultimately in hypertension and proteinuria (pre-
eclampsia) (Govender et al., 2013; Wang et al., 2009).  
 
Decreased levels of sFlt1 in early pregnancy have been associated with decreased foetal 
cytotrophoblast invasion into maternal spiral arteries. Endoglin is a surface receptor for TGF-
beta. TGF-β 1 and/or TGF-β 3 inhibits trophoblast migration and invasion (Ajith et al., 2014). 
The placenta may produce sEng to compensate for the increased surface endoglin which results 
in increased sEng in the maternal circulation in pre-eclamptic women (Govender et al., 2015; 
Wang et al., 2009).  
 
1.5.4 Genetic factors contributing to pre-eclampsia 
Pre-eclampsia often occurs in young women in their first pregnancy. The maternal immune 
system develops tolerance to the paternal alloantigens when exposed to seminal fluid and/or 
semen (Chelbi and Vaiman, 2008). Prolonged exposure to semen reduces the risk of pre-
eclampsia, in contrast primigravid women and women undergoing artificial insemination have a 
higher risk of developing pre-eclampsia (Chaiworapongsa et al., 2014).  
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Anyikam et al. (2004) reporteded that women with ≥3 genderual partners are at a higher risk of 
developing pre-eclampsia than women with ≤2 genderual partners. Also, women experiencing 
menarche at ≤12 years are at a higher risk of pre-eclampsia development than women at later 
ages. Moodley (2008) reporteds that teenage pregnancies are at risk of developing pre-eclampsia. 
 
Other risk factors of pre-eclampsia include extreme maternal ages (<20 years or >35 years), 
history of pre-eclampsia in previous pregnancy, multi foetal gestation, obesity, family history of 
pre-eclampsia, pre-existing medical conditions such as chronic hypertension, diabetes mellitus, 
antiphospholipid syndrome, thrombophilia, autoimmune disease, renal disease and infertility and 
urinary tract infection (Chaiworapongsa et al., 2014; Sanchez-Aranguren, 2014).  
 
1.5.5 Oxidative stress 
The traditional understanding of the pathophysiology of pre-eclampsia is that the ischemic 
placenta produces soluble toxins into the maternal circulation which are responsible for the 
clinical presentation of the disease (Siddiqui et al., 2010). These soluble factors cause endothelial 
dysfunction, intravascular inflammation and an activation of the haemostatic system. Pre-
eclampsia is therefore considered primarily to be a vascular disorder (Sanchez-Aranguren, 2014). 
The clinical manifestations result from the involvement of multiple organs such as the kidneys, 




1.5.6 Immune maladaptation 
1.5.6.1 Cytokine production in pre-eclampsia 
Pre-eclampsia is associated with exaggerated inflammation and increased production of 
cytokines (Bachmayer et al., 2009), the role of which remains controversial (Mansouri et al., 
2007). T-helper (h)1 and Th2 cytokines play a role in cell-mediated and humoral immunity 
respectively. Th1 immune response inhibits Th2 response and vice versa through the production 
of cytokines therefore many immune responses tend to be dominated by one or the other cell 
type (Mikovits et al., 1994).   
 
In healthy non-pregnant women there is a balance between the Th1 and Th2 response 
(Laresgoiti-Servitje et al., 2010). However, in successful normal pregnancy, with the presence of 
the placenta there is a shift from the Th1 to Th2 immune response (Figure 1.5, Laresgoiti-
Servitje et al., 2010). In pathological pregnancies such as pre-eclampsia, spontaneous abortions 
and IUGR, the regulation of the maternal immune system is further altered and the shift to the 
Th2 immune response does not occur (Figure 1.5) (Hu et al., 2007). Wegmann et al. (1993) 
proposed that the placenta is a Th2 organ that stimulates the production of Th2 cytokines in the 
maternal immune system. When the placenta is abnormal, the maternal immune system responds 
by producing Th1 cytokines. Additionally, transforming growth factor-β cytokines surge thereby 
retarding cytotrohophoblast migration (Fukui et al., 2011; Laresgoiti-Servitje et al., 2010). 
Moreover, syncytiotrophoblast debris is increased in pre-eclamptic maternal circulation due to 
the ischemic placenta which is possibly responsible for triggering the Th1 response (Sargent, et 




Th2 cytokines respond to extracellular infection and are known to suppress the immune system 
(Becker, 2004). In HIV infected patients there is a decrease in the Th1 and an increase in Th2 
cytokines (Clerichi and Shearer, 1993). There are however, conflicting reporteds on the 
circulating levels of cytokines in pre-eclampsia (Kumar et al., 2013). 
 
 
Figure 1.5: Th1 and Th2 response in normal and pathological pregnancy. In successful normal 
pregnancy there is a shift from the Th1 to a Th2 immune response with an increased production 
of Th2 cytokines. In pre-eclampsia the shift to a Th2 immune response does not occur resulting 




1.5.6.2 Natural Killer cell production in pre-eclampsia 
The two interfaces of pregnancy are the invasive extravillous foetal cytotrophoblast and the 
maternal immune cells at the decidua (Sargent et al., 2007). The most abundant lymphoid cell 
population at the decidua is the decidual Natural Killer (NK) cells which interact with the major 
histocompatibility complex (MHC) antigens through receptors such as Human Leukocyte 
Antigen (HLA)-E and CD94/NKG2A (Sargent et al., 2007). 
 
Natural Killer cells are triggered by cytokines, interleukin (IL)-2, IL-12, IL-15 and IL-18 (Vacca 
et al., 2011). Once activated NK cells express CD69 which activate interferon (IFN)-γ 
production that contribute to a Th1 immune response in circulation in pre-eclampsia (Bachmayer 
et al., 2009). IFN-γ expression was also found to be higher at the decidua in pre-eclampsia 
(Darmochwal-Kolarz and Kludka-Sternik, 2010). NK cells play a crucial role at the decidual and 
syncytiotrophoblast interface and abnormal activation of NK cells results in pre-eclampsia 
development (Sargent et al., 2007). 
 
1.6 NATURAL KILLER CELLS 
Natural Killer (NK) cells are large granular lymphocytes that comprise 10% of total blood 
lymphocytes, 70% T cells and 20% B cells (Acar et al., 2011). NK cells are the first line of 
defense against infection. Natural Killer cells that target viral and tumour cells, are recruited to 
the site of infection or to the transformed cells where they recruit and activate other immune cells 
(Vacca et al., 2013). These cells are cytotoxic and function by releasing proteins from 
cytoplasmic granules such as perforin and granzyme which lyse target cells (Acar et al., 2011). 
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1.6.1 Mechanism of Natural Killer cell recognition  
Natural Killer (NK) cells are an important part of the innate immune system which provide an 
immediate defense against infection (Figure 1.6). In contrast the adaptive immune system 
provides long lasting immunity to the host. NK cells do not require activation to kill cells that are 
missing self-markers of MHC class I. This is important because harmful cells missing MHC I 
cannot be detected and destroyed by other immune cells such as T lymphocytes. There are two 
distinct mechanisms by which NK cells kill their target viz., antibody-dependent cell mediated 
cytotoxicity (ADCC) and their “Natural Killer” activity (Acar et al., 2011). 
 
 




1.6.2 Classification of Natural Killer cells 
Natural Killer cells are characterized by the absence of CD3 and presence of the CD56 surface 
antigen. CD16 are present on the surface of NK cells and are involved in antibody-dependent 
cellular cytotoxicity (Acar et al., 2011). There are two types of NK cells namely, uterine and 
peripheral NK cells. Uterine NK cells (uNK) constitute 70-90% of all blood lymphocytes whilst 
peripheral NK cells (pNK) constitute 5-10% (Fukui et al., 2011). NK cells occur either as 
CD56bright or CD56dim (Figure 1.7). The former are the major pro-inflammatory cytokine 
producers, are less cytotoxic and found mainly in the decidua whilst the latter are cytotoxic, 







Figure 1.7: Natural Killer cells and receptors. CD56bright NK cells produce more cytokines 
compared to the CD56dim NK cells which are cytotoxic. Each NK cell has its own inhibiting and 
activating receptors (Cooper et al., 2001). 
 
1.6.3 Natural Killer cell receptors 
The activity of NK cells are regulated by inhibitory and activating receptors. Each NK cell 
expresses its own inhibitory and activating receptors (Cooper et al., 2001). NK cell activating 
receptors are the natural cytotoxicity receptors viz., NKp46, NKp30, NKp44, NKG2D, CD16, 
2B4, NTBA, CD69, NKp80 and DNAM-1. Inhibitory receptors include HLA class I molecules, 
p75/AIRM1 (Siglec-7) and IRP60 (Vacca et al., 2011). There are three families of NK cell 
receptors, namely killer-cell immunoglobulin-like receptors (KIRs), C-type lectin receptors, 
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CD94/NKG2 (NKG2A-F, Figure 1.7) and immunoglobulin-like transcripts (ILTs) (Acar et al., 
2011) and natural cytotoxicity receptors (NCRs) which regulate NK cell cytotoxicity and 
cytokine production (Fukui et al., 2012).  
 
Killer-cell Ig-like receptors (KIRs) are type I transmembrane glycoproteins and are classified by 
the number of Ig-like domains, two (KIR2D) or three (KIR3D) and by the presence of long 
(KIR2DL and KIR3DL) or short (KIR2DS and KIR3DS) cytoplasmic tails. KIRs with long tails 
are associated with inhibition of NK cell mediated cytotoxicity and cytokine secretion whilst the 
short tails are associated with NK cytolysis. KIR2D receptors recognize HLA-C alleles and 
KIR3D receptors recognize HLA-A and HLA-B alleles (Sánchez-Rodríguez et al., 2011). The 
interaction between maternal KIRs and trophoblast cells play a physiological role in placental 
development. In mothers lacking most or all the activating KIRs, their fetuses possess HLA-C 
and show greater risk of pre-eclampsia development (Acar et al., 2011). Yan et al. (2007) 
showed higher KIR2DL4 protein levels in normal pregnancies compared to recurrent 
spontaneous abortion patients whilst Witt et al. (2004) showed no differences.  
 
CD94/NKG2 receptor is a member of the C-type lectin superfamily. The NKG2 family 
comprises five genes, NKG2A, NKG2C, NKG2D, NKG2E and NKG2F which determine 
whether the receptor is inhibitory or activating. CD94/NKG2 receptors include NKG2A/B which 
provides an inhibitory signal and inhibits NK function whilst NKG2C and NKG2D are NK cell 
activating receptors (Bachmayer et al., 2009). CD56dim NK cells express the inhibitory killer cell 
immunoglobulin-like receptors (KIR) which are found predominately in the peripheral blood. 
CD56bright lack KIR expression but express high levels of the activating CD94/NKG2 receptors 
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which are found in the peripheral tissues. These receptors play an important role in the formation 
of the decidua and placenta (Bachmayer et al., 2006).  
 
ILT genes are also known as leucocyte Ig-like receptors (LIRs). They are expressed on B cells, T 
cells, NK cells, dendritic cells, monocytes and macrophages. They consist of eight members, 
LIR-1-8 and only IL2 and 4 bind to HLA class I molecules including HLA-G (Acar et al., 2011). 
In normal pregnancy, HLA-G with the aid of ILT4 receptor modulates the behavior of dendritic 
cells, monocytes and macrophages. The role of ILT receptors in pre-eclampsia is yet to be 
determined (Laresgoiti-Servitje et al., 2010). 
 
1.6.4 The role of NK cell receptors in HIV  
NK cells may recognize cells under stress by expression of their ligands by means of NK cell 
receptors such as KIRs (NKRs) (Naranbhai et al., 2013). Viruses have evolved specific 
mechanisms to reduce the expression of HLA which is a KIR ligand (Naranbhai et al., 2013). 
The mechanism by which HIV suppresses NK cell activity is not known. IFN-γ NK cell 
responses may protect against HIV infection (Tiemessen et al., 2001). 
 
1.6.5 Functions of Natural Killer cells in pregnancy  
In early pregnancy, the major subset of uNK cells is CD16- and CD160- whilst that of pNK cells 
is CD16+ and CD160+ (Le Bouteiller et al., 2011). In normal pregnancies, despite the fetus being 
semi-allogeneic, it escapes rejection from the maternal immune system (Vacca et al., 2011). 
Leukocytes such as Natural Killer cells, CD14+ myelomonocytic (dCD14+) cells and T 
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lymphocytes play a role in establishing and maintaining maternal immuno-tolerance (Vacca et 
al., 2011).  
 
NK cells also play an important role in ensuring reproductive success (Fukui et al., 2011). In 
early pregnancy NK cells within the decidua are known to play a role in placentation, 
angiogenesis and in the regulation of trophoblast invasion (Bachmayer et al., 2009). CD56+ 
aggregates have been observed around spiral arteries and glands. The number of uNK cells 
decline after 20 weeks of gestation when trophoblast invasion is complete (Acar et al., 2011). 
Although studies have indicated a beneficial role of uNK cells in ensuring pregnancy success, 
the function of pNK cells is not well known (Fukui et al., 2011).   
 
1.7 UTERINE NATURAL KILLER CELLS 
Uterine Natural Killer cells located within the non-pregnant endometrium are called endometrial 
NK cells whilst in the decidua are called decidual NK (dNK) cells.  Uterine Natural Killer cells 
constitute the major lymphocyte population in early gestation in the uterus which decreases after 
20 weeks of gestation when trophoblast invasion is complete (Acar et al., 2011). 
 
Uterine Natural Killer cells are characterized as CD56bright, CD16- and CD3-. They are less 
cytotoxic and produce large amounts of cytokines compared to peripheral Natural Killer cells. 
Many studies have shown that CD56bright CD16- uNK cells originate in the blood from CD56bright 
CD16- NK cells (Acar et al., 2011) whilst Keskin et al. (2007) suggest that uNK cells may 
originate from CD56dim CD16+ pNK cells in the blood and differentiate in tissue by TGF-β and 
other factors. Uterine NK cells may differentiate from precursor cells in the uterus (Acar et al., 
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2011). CD56bright cells in peripheral blood are agranular compared to uterine tissue where they 
are granular (Fukui et al., 2011). 
 
1.7.1 Receptors of uterine Natural Killer cells 
The trophoblast is the outermost layer of the placenta and is in direct contact with the maternal 
immune system (Vacca et al., 2011). The human trophoblast lacks HLA-A, -B but express HLA-
C, -E and –G. Both maternal KIR genotype and foetal HLA molecules can result in NK cell 
inhibition and may be associated with high risk of pre-eclampsia due to inadequate trophoblast 
invasion and spiral artery transformation (Koopman et al., 2003).   
 
Trophoblast cells express ligands for activating NK receptors such as NCRs, DNAM-1 and 
NKG2D. When dNK cells interact with the trophoblast they release IL-8, VEGF, SDF-1 and 
IP10. This interaction facilitates trophoblast migration, angiogenesis and the remodeling of the 





Figure 1.8: The interaction between uterine Natural Killer cell receptors and trophoblast cells in 
ensuring successful placental development (Vacca et al., 2011). 
 
Despite having cytotoxic properties, uNK cells appear to be important regulators of implantation 
and successful pregnancies (Acar et al., 2011). The number and range of uNK receptors differ 
between normal and pathological pregnancies, such as pre-eclampsia or intrauterine growth 
(Acar et al., 2011). Le Bouteiller et al. (2011) have shown that the interaction between the 
cytotoxic uNK, NKp46 activating receptor and CD94/NKG2A with its HLA-E ligand inhibits 
the cytolytic action of uNK cells in a non-infected pregnant uterus. NKG2A inhibitory receptor 
and its HLA-E ligand expressed by trophoblast and other decidual cells inhibit the cytotoxic 
activity of the NKp46 receptor of uNK cells.  uNK cells produce cytokines and chemokines by 
interacting with ligands of receptors expressed by trophoblast and decidual stromal cells (Le 




1.7.2 Functions of uterine Natural Killer cells 
Uterine Natural Killer cells are the major lymphocyte population found during early gestation in 
the uterus and decreases as pregnancy progresses (Fukui et al., 2012). These cells occur in the 
endometrium, however they have shown to play a role in trophoblast invasion and spiral 
remodeling which occurs in the inner myometrium where uNK cells have not been found (Acar 
et al., 2011). They occur in abundance at the maternal-foetal interface in close proximity to 
extravillous trophoblast cells and play an important role in implantation and in placental 
development (Lash et al., 2010).  
 
Uterine Natural Killer cells, increase during the differentiation of the human endometrial 
epithelium and produce angiogenic factors such as angiopoietin (Ang) 1, Ang 2, vascular 
endothelial growth factor (VEGF), placental growth factor (PIGF) and TGF-β and cytokines 
such as IL-8 and IFN-inducible protein 10 which play an important role in angiogenesis (Acar et 
al., 2011; Fukui et al., 2012).  
 
Uterine Natural Killer cells may contribute to pre-eclampsia by inducing the lysis of trophoblast 
cells lacking HLA-G (Vacca et al., 2011). Fewer trophoblast cells will then invade the maternal 
spiral arteries which results in lack of oxygen and nutrients to the fetus (Vacca et al., 2011). 
 
1.8 PERIPHERAL NATURAL KILLER CELLS 
Peripheral Natural Killer (pNK) cells are characterized as CD56dim and CD16+ cells and are 
mostly cytotoxic and release IFN-α rapidly on activation. Although NK cells are abundantly 
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found in peripheral blood, they primarily exert their function in tissues and secondary lymphoid 
organs in response to inflammation (Vacca et al., 2011).   
 
Eriksson et al. (2006) showed that CD56bright pNK and uNK cells shared positive expression of 
surface markers CD56 and CD94, negative expression of CD57 and negative or low expression 
of CD16 (Acar et al., 2011). Uterine NK cells are differentiated from pNK cells by the 
expression of CD9 (Acar et al., 2011).  
 
1.8.1 Receptors of peripheral Natural Killer cells 
CD56dim NK cells express high levels of killer-immunoglobulin-like receptors (KIRs) and low 
levels of NKG2A. Bachmayer et al. (2009) reporteded that levels of inhibitory NKG2A and 
activating NKG2C were higher in pre-eclamptic compared to normal pregnant women (Vacca et 
al., 2011). Mela et al. (2007) have shown decreased expression of NKG2A on pNK cells of HIV-
1 infected individuals (Le Bouteiller et al., 2011). 
 
1.8.2 Functions of peripheral Natural Killer cells 
Natural Killer cell expression is important for successful pregnancy (Mosimann et al., 2013) and 
have shown that CD56dimCD16+ cells were significantly higher than CD56dimCD16- cells in 
peripheral blood in reproductive failures compared to successful pregnancies (Vacca et al., 
2011).  
 
The interaction between peripheral blood NK cells and trophoblasts is not well understood. NK 
cells preferentially kill targets with lower expression of major histocompatibility complex 
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(MHC) class I proteins, because fewer inhibitory receptors are engaging ligands. As a 
consequence, syncytiotrophoblasts are vulnerable to cytotoxic effect of peripheral blood NK 
cells (Fukui et al., 2011). Moreover, Moffett et al. (2004) reporteded that examination of 
peripheral blood NK cells is not informative of what is actually happening within the uterus.  
 
Abnormalities in NK cell response amongst other immune responses may cause hypertension 
and high levels of proteinuria with consequential placental dysfunction and resultant pre-
eclampsia (Cerdeira and Karumanchi, 2012). Some studies have also shown the abnormal 
production of angiogenic factors by peripheral NK cells (Fukui et al., 2012). Molvarec et al. 
(2010) has shown that pNK cells produce lower levels of VEGF in pre-eclamptic women 
compared to healthy pregnant women (Vacca et al., 2011).  Peripheral Natural Killer cells 
secrete MIP-1α and MIP-1β ligands of CCR5 which inhibit viral entry and GM-CSF which 













Table 1.1 Phenotype and functions of uNK and pNK cells (Vacca et al., 2011) 
Phenotype uNK pNK pNK 
  
CD56bright CD56dim 
CD16 − −/+ ++ 
CD94/NKG2 ++ ++ − 
KIRsa + − + 
KIR2DL4 + − − 
CD9 + − − 
CD151 + − − 
CD69 + − − 
CD49a + − − 
CD49f − + + 
CD62L (L-Selectin) − + −/+ 
Granzymes and Perforin ++ −/+ ++ 
Functions 
   Cytotoxicity −/+ −/+ ++ 
IFN-γ + ++ 
 GM-CSF ++ + + 
IL-8 +++ − − 
IP10 + − − 
VEGF ++ − − 
 




1.9 NATURAL KILLER CELLS AND HIV ASSOCIATED PRE-ECLAMPSIA 
Although the role of Natural Killer cells is to destroy viral cells, HIV has the ability to suppress 
the function of NK cells. NK cells function by the interaction of their activating receptors with 
cell surface ligands either of the infected host cells or by the virus itself (Figure 1.9, Le 
Bouteiller et al., 2011). The integration of inhibiting and activating receptor signals determines 
NK cell anti-viral response (Le Bouteiller et al., 2011).  
 
 
Figure 1.9: NK cell receptor mediated protection in HIV-infection (Le Bouteiller et al., 2011). 
 
Although the role of NK cells in HIV infection is well documented, its function in HIV 
associated pre-eclampsia has produced conflicting results (Conde-Agudelo et al., 2008).  
Antiretroviral therapy has been implicated in the rate of pre-eclampsia development (Kalumba, 
2012). Other studies reporteded that there is no difference in treated and untreated HIV infection 
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in pre-eclampsia (Mattar et al., 2004). Kalumba, 2012 showed that HIV positive women were 






The population of peripheral NK cells are higher in HIV positive pre-eclamptic than HIV 
positive normotensive pregnant women. 
 
1.11 NULL HYPOTHESIS 
There is no correlation between Th1 and Th2 cytokines with NK cells (CD3-, CD56dim and 
CD16+) and NK receptor expression (CD69, CD94, NKG2A, NKG2C and NKG2D) across all 
study groups.  
 
1.12 AIM OF THE STUDY 
The aim of the study is to determine the correlation between the phenotypic properties of 
peripheral Natural Killer (NK) cells (CD3-, CD56dim and CD16+) and their receptors (NKG2A 
and NKG2C) with Th1 and Th2 cytokine expression in pre-eclamptic (early and late onset) and 
normotensive pregnant Black South Africans infected and uninfected with HIV. 
 
1.13 SPECIFIC OBJECTIVES 
 To quantitate peripheral NK cell (CD3-, CD56dim and CD16+) and their receptor (CD69, CD94, 
NKG2A, NKG2C, NKG2D) expression in immunocompromised normotensive pregnant vs pre-
eclamptic (early and late onset) Black South Africans.   
 To compare the maternal serum levels of Th1 (IL-2, IL-12(70), IFN-γ, TNF-α, and GM-CSF,) 
and Th2 (IL-4, IL-5, IL-10, p=0.795 and IL-13) cytokines across all six study groups. 
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 To correlate the expression of the Th1 (IL-2, IL-12(70), IFN-γ, TNF-α, and GM-CSF,) and Th2 
(IL-4, IL-5, IL-10, p=0.795 and IL-13) cytokines with NK cell (CD3-, CD56dim and CD16+) and 
their receptor (CD69, CD94, NKG2A, NKG2C, NKG2D) expression across all six study groups.  
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CHAPTER TWO  
METHODS 
 
2.1 ETHICAL APPROVAL 
This study received postgraduate approval from the School of Laboratory Medicine and Medical 
Sciences, College of Health Sciences at the University of KwaZulu-Natal (UKZN; Addendum I). 
Ethical approval was obtained from UKZN Biomedical Research Ethics Committee (BREC 
reference no: BE176/13; Addendum II).  Additionally, Department of Health (Addendum III) 
and Hospital Manager approval from Prince Mshiyeni Memorial Hospital (Addendum IV) were 
obtained before recruitment of patients. Study information was given and informed consent 
(Addendum V) was obtained for participation in the study.  
 
2.2 RECRUITMENT OF PATIENTS 
Primigravid and multigravid pre-eclamptic and normotensive pregnant HIV positive and 
negative Black South Africans were recruited from Prince Mshiyeni Memorial Hospital, Umlazi, 
Durban. Prince Mshiyeni Memorial Hospital is a district and regional hospital in eThekwini 
which serves the catchment area and part of the Eastern Cape.  Purposeful sampling was used to 
recruit patients based on the inclusion and exclusion criteria outlined in 2.2.1. The research 
assistant identified potential study patients. Only those patients that fulfilled the criteria were 
recruited to the study. These patients were either recruited directly from the labour ward or from 
the ante natal clinic. Both pre-eclamptic and normotensive groups consisted of HIV positive and 




2.2.1 Inclusion criteria and study population  
Primigravid and multigravid patients with a diagnosis of pre-eclampsia (new onset blood 
pressure of ≥140/90 mmHg and at least 1+ proteinuria) formed the study group. For analysis, 
participants were grouped into early or late-onset pre-eclampsia that is ≤ 33 weeks and ≥ 34 
weeks of gestation respectively. The control group consisted of healthy, primigravid and 
multigravid normotensive patients with a blood pressure of ≤120/80 mmHg. Only Black 
patients’ ≥18 years were included in the study. The rationale for inclusion of Black African 
patients was that a higher percentage of Black African women compared to other ethnic groups 
attend Prince Mshiyeni Memorial Hospital. Thus, this site selection enabled us to maintain ethnic 
homogeneity of our study population. Infection with human immunodeficiency virus was based 
on CD4+ cell count. 
 
The study groups are outlined below:  
 

































2.2.2 Exclusion criteria 
Non-Black African patients, ˂18 years of age and those who declined entry into the study were 
excluded. Exclusion criteria for the pre-eclamptic group included polycystic ovarian syndrome 
patients, chorioamnionitis, chronic hypertension, eclampsia, abruption placentae, intrauterine 
death, pre-gestational diabetes, gestational diabetes, chronic diabetics, chronic renal disease, 
systemic lupus erythematous, sickle cell disease, antiphospholipid antibody syndrome, thyroid 
disease, cardiac disease, active asthma requiring medication during pregnancy, pre-existing 
seizure disorder, HIV status unknown and unbooked patients.  
 
2.3 SAMPLE COLLECTION  
Patient demographics were recorded on the patient data form by the clinical research assistant. 
The following information was recorded: maternal age, parity, gravidity, gestational age, blood 
pressure, proteinuria, height, weight, BMI (body mass index), HIV status and CD4+ cell counts, 
obstetric and neonatal outcomes and maternal and neonatal complications (Addendum VI).  
 
Blood samples were collected by the clinical research assistants. During routine blood tests, an 
additional 9 ml of blood was drawn aseptically. Four ml of blood was collected in a sterile 
tripotassium ethylenediamine tetra-acetic acid (K3 EDTA) vacutainer blood collection tube 
(Greiner Bio-One, USA) for multicolour flow cytometry analysis and 5 ml in a sterile serum 
separating tube (SST; Greiner Bio-One, USA) without anticoagulant for multiplex enzyme-
linked immunosorbent assay (ELISA) analysis.  
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2.4 QUANTIFICATION OF PERIPHERAL NATURAL KILLER CELLS USING 
MULTICOLOUR FLOW CYTOMETRY 
2.4.1 Principle of multicolour flow cytometry 
The BDLSRFortessaTM flow cytometer (Becton, Dickinson and Company, San Jose, CA 95131 
USA) was used for the multicolour flow cytometry analysis. Fluorochromes such as 
allophycocyanin (APC), fluorescein isothiocyanate (FITC) or phycoerythrin (PE) are covalently 
conjugated to a monoclonal antibody that binds onto a specific antigen. Fluorochrome stained 
cells as sample pass through the instrument in a single file. A laser light source passes through 
and activates the stained cells and the forward and side scattered light (fluorescence) from all 
cells is detected and emitted at a particular wavelength. The forward scatter determines the 
relative cell size whilst the side scatter determines the granularity of a cell. The fluorescence 
emitted from the stained cells is guided through a series of filters and mirrors to a 
photomultiplier tube, which detects the photons, amplifies the signal and converts it to an 
electrical signal. This is converted to a digital signal that is analysed by the FACSDiva™ 
Software (Becton, Dickinson and Company, San Jose, CA 95131 USA; Brown and Whittwer, 




Figure 2.2: Principle of multicolour flow cytometry. The laser excites the fluorochrome 
conjugated to the antibodies as the cells pass through the instrument in a single file. The emitted 
light is detected by a series of filters and dichroic filters and detected by photomultiplier tubes as 
an electronic impulse is captured for data analysis (Brown and Wittwer, 2000); 
http://www.rudbeck.uu.se/node47). 
 
2.4.2 Estimation of peripheral Natural Killer cells (CD3-, CD56dim, CD16+) and its receptors 
(CD69, CD94, NKG2A, NKG2C and NKG2D) 
2.4.2.1 Optimising antibody dilutions  
Doubling dilutions were used to determine the optimal antibody concentrations for the 
determination of peripheral NK cells using multicolour flow cytometry analysis. Five Falcon 
tubes (5 ml) (Becton, Dickinson and Company, Franklin Lakes, NJ 07417 USA) were labeled 
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and 20 µl of staining buffer (1x phosphate-buffered saline, LONZA BioWhittaker®, Belgium + 
0.1% (w/v) sodium azide, Sigma-Aldrich®, Saint Louis, MO 63103, USA) was added to each 
tube. To tube one, 10 µl of antibody solution and 10 µl of staining buffer were added, to make a 
final volume of 40 µl. The tube was vortexed gently using the Vortex-Genie® 2 (Scientific 
Industries, INC, USA) and 20 µl of solution was transferred from tube 1 to tube 2. Tube 2 was 
mixed by vortexing and 20 µl of solution was transferred from tube 2 to tube 3. This was 
repeated for tube 4 and 5 and 20 µl from tube 5 was discarded to maintain a total volume of 40 
µl per tube. Staining and lysis of blood samples were as outlined below.   
 
2.4.2.2 Procedure for setting compensation  
Compensation is the electronic subtraction of spillover from the different fluorochromes utilized 
in the multicolour flow cytometry analysis. The BDTM CompBeads (Becton, Dickinson and 
Company, San Diego, CA 92121, USA) were vortexed thoroughly before use. A Falcon tube for 
each fluorochrome conjugated antibody (Table 2.1) was labelled. To each tube, 100 µl of 
staining buffer and one drop of the BDTMCompBead Negative control and one drop BDTM 
CompBeads Anti-Mouse Ig, κ were added. Each antibody was added to the appropriate tubes 
containing the beads, vortexed and incubated for 30 minutes at room temperature. During 
incubation the BDTM CompBead Negative control was used to set the flow cytometer instrument 
photomultiplier tube voltage settings. Following incubation, 2 ml of staining buffer was added to 
each tube and centrifuged at 200 x g (1092.06 rpm) for 10 minutes (Eppendorf centrifuge 5804R, 
Hamburg, Germany). The supernatant from each tube was carefully removed with a 3 ml Pasteur 
pipette (Lasec SA (Pty) Ltd, SA) and each pellet was suspended in 0.5 ml staining buffer and 
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vortexed thoroughly. Based on the forward and side scatter a singlet bead population was gated 
from which a negative and positive bead population were determined. 
 
Table 2.1: Fluorochrome conjugated antibodies and dilutions used for multicolour flow 
cytometry analysis  
Antibody Fluorochrome*  Dilution (µl) 
CD3 BD Horizon V500# 3.0  
CD16 FITC# 5.0 
CD56 Pe-Cy7# 1.5 
CD69 Brilliant VioletTM 421# 3.0 
CD94 PerCP-Cy5.5# 2.5 
NKG2A Alexa Fluor® 500^ 2.5 
NKG2C PE^ 5.0 
NKG2D APC# 10.0 
*The brighter fluorochromes were conjugated to the smaller expected antibody population and vice versa.  
# Becton, Dickinson and Company, San Jose, CA 95131 USA 
^R&D Systems®, Minneapolis, MN 55413, USA 
 
2.4.2.3 Staining and lysis of maternal whole blood  
Blood samples were collected in 4 ml K3 EDTA vacutainer sterile blood collection tubes. 
Conjugated antibodies were titrated (1.5-10 µl) (Table 2.1) before staining 300 µl of blood 
sample. The samples were vortexed and incubated for 30 minutes in the dark at room 
temperature. BDFACS™ lysing solution (2 ml) (Becton, Dickinson and Company, San Jose, CA 
95131 USA) was added to the samples, vortexed and incubated for 10 minutes in the dark at 
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room temperature. Samples were then centrifuged at 500 x g for 5 minutes and the supernatant 
was removed. Samples were washed with staining buffer, centrifuged at 500 x g for 5 minutes 
and the supernatant removed for analysis on the BDLSRFortessaTM flow cytometer. Fluoresence 
minus one (FMO) controls were used to ensure correct interpretation of the data. These controls 
contain all the fluorochromes to be used in the experiment except one that is measured. This is 
used to identify the spread of a flurochrome into a channel of interest. SpheroTM Rainbow 
Fluorescent Particles, 3.0-3.4 µm (mid-range F1 fluoresence) (Becton, Dickinson and Company, 
San Diego, CA 92121, USA), three drops were used for each multicolour flow cytometry 
analysis. These beads are single bead population particles dyed with several fluorescence 
intensities to ensure calibration of the flow cytometer. 
 
2.4.3 Analyses 
The data was captured from the BDLSRFortessaTM flow cytometer with the FACSDiva™ 
software and analysed using FloJo, LLC Data Analysis Software Version X (Oregon, USA). 
Lymphocytes were identified using forward scatter/side scatter (FSC/SSC) and the CD3- 
population was identified (Mosimann et al., 2013). Peripheral NK cells were further classified as 
CD16+ and CD56dim. From this population the CD69, CD94, NKG2A, NKG2C and NKG2D 
receptors were determined. This data was entered into an Excel spreadsheet and analysed using 








Figure 2.3: Gating strategy used to analyse Natural Killer cells, peripheral Natural Killer cells 
and its receptors. P1 gate represents lymphocytes, P2 single cells, P3 Natural Killer (CD3-) cells, 
P4 peripheral Natural Killer (CD56dimCD16+) cells, P4 CD94 inhibiting receptor, P5 CD69 
activating receptor, P6 NKG2A inhibiting receptor, P7 NKG2C stimulatory receptor and P8 






2.5 QUANTIFICATION OF MATERNAL SERUM TH1 AND TH2 CYTOKINES USING 
MULTIPLEX ELISA 
2.5.1 Principle of multiplex ELISA 
The Bio-Plex® suspension array system uses Luminex xMAP technology that allows 100 
different analytes which are uniquely bound by 100 different fluorescently dyed beads to be 
simultaneously detected in one well of a 96 well plate. The system has two lasers and associated 
optics to detect the molecules bound to the beads and a signal processor to manage the 
fluorescent output. The principle of multiplex ELISA is similar to a sandwich immunoassay 
where an antibody covalently coupled to a dyed bead reacts with a sample containing the desired 
cytokine. A sandwich of antibodies is formed when a biotinylated detection antibody specific for 
a different epitope is added to the reaction. Streptavidin-phycoerythrin (streptavidin-PE) is added 
and binds to the biotinylated detection antibodies on the beads surface to increase sensitivity and 
increase signal output. The data was captured on the Bio-Plex®MAGPIXTM Multiplex Reader 
(Luminex system; Bio-Rad Laboratories Inc., Hercules, CA 94547, USA) where the lasers and 
optics detect the fluorescently dyed beads and the signal from the beads represents each target 
protein in the well. The intensity of the fluorescence indicates the quantity of the target protein in 
the sample. The fluorescence intensity (data output) is managed by a processor and captured on 






Figure 2.4: Principle of multiplex Luminex assay. Luminex xMap technology uses the same 
principle as simple ELISAs, however different analytes are attached to multiple fluorescent 
beads and detection antibodies which allows for the simultaneous quantification of multiple 
analytes in a single well.  
 
2.5.2 Separation of serum from maternal whole blood 
Blood collected in serum separation tubes within 4 hours were centrifuged at 3000 rpm for 10 
minutes at 4°C in the Eppendorf centrifuge 5804R. The supernatant containing the serum was 
transferred to a clean polypropylene tube using a 3 ml Pasteur pipette and stored in 0.5 ml 







Figure 2.5: Separation of maternal serum from whole blood. Whole blood is allowed to clot and 
the clot is removed by centrifugation. The resulting supernatant called serum is removed with a 
Pasteur pipette. 
 
2.5.3 Procedure for the estimation of the Th1 and Th2 cytokines 
The Bio-Plex Pro™ Human Cytokine Th1/Th2 Panel, 9-Plex was used (Bio-Rad Laboratries, Inc, 
USA) to determine the quantity of the Th1 (IL-2, IL-12(70), IFN-γ, TNF-α, and GM-CSF) and 
Th2 (IL-4, IL-5, IL-10, and IL-13) cytokines. The 1x diluted beads (50 µl) were added to each 
well of the 96 well plate. The plate was washed twice with 100 µl of Bio-Plex wash buffer and 
covered with foil to protect from light. The standards, serum samples and a blank (standard 
diluent), 50 µl each were added to each well. The plate was sealed with sealing tape, covered 
with foil and incubated on a shaker (Stat Fax™ 2200, 220 V Incubator/Shaker, Califirnia, USA) 
at 850 rpm for 30 minutes at room temperature. The plate was washed three times with 100 µl of 
wash buffer per well with the Bio-Rad Bio-Plex Pro™ II Wash station (Bio-Rad Laboratries, Inc, 
USA). The 10x detection antibodies (25 µl) were added to each well and incubated for 30 
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minutes at room temperature. The plate was washed with 100 µl of wash buffer three times 
before adding 50 µl of 1x streptavidin alkaline phosphatase (SAPE) to each well and incubated 
for 10 minutes at room temperature. The beads were then re-suspended in 125 µl assay buffer 
and incubated on a shaker at 850 rpm for 2 minutes at room temperature. The plate was read 











Figure 2.6: Procedure for multiplex Luminex method. Diluted beads are added to each well 
before the standards, serum samples and blanks are plated. Plate is incubated and washed. The 
detection antibodies are added to each well after which Streptavidin-phycoerythrin (SAPE) is 
added to each well and re-suspended in assay buffer prior to analysis on the Bio-




Bio-Plex®MAGPIXTM Multiplex Reader and 






A protocol was created on the software package, Bio-Plex ManagerTM software version 6.1 
which was used to obtain the data from the multiplex ELISA analysis. The known concentration 
(pg/ml) of each analyte was used to generate a standard curve for each cytokine by plotting the 
median fluorescent intensity (MFI) signal against concentration (Held, 2014). These standards 
were used to interpolate the concentrations of the unknown samples. Inter- and intra-plate 
variability were determined with CV ˂20% and (Obs/Expected)*100 between 70-130% (r=0.8, 
p=0.05). The data was imported into an Excel spreadsheet for statistical analysis.  
 
2.6 STATISTICAL ANALYSIS 
IBM SPSS Statistics Version 23 was used to analyze the data. Descriptive statistics for 
continuous data is presented either by mean±standard deviation or median (range). To determine 
the statistical difference between study groups, the Mann Whitney U and Kruskal-Wallis test 
were used for non-parametric data and Independent samples t-test and ANOVA for parametric 
data. For correlation between cytokines and NK cells and receptor expression, Pearson 
correlation coefficient for parametric data and Spearman rank correlation for non-parametric data 
was used. Categorical data was presented in frequency tables displaying n (%). Pearson’s Chi 





CHAPTER THREE  
RESULTS 
 
3.1 STUDY POPULATION 
The total study population comprised of 255 Black South African women of which 101 (39.61%) 
were normotensive and 154 (60.39%) pre-eclamptic. The latter group was sub-stratified into 
early and late onset pre-eclampsia (EOPE and LOPE) comprising 81 (52.60%) and 73 (47.40%) 
women respectively. The normotensive and pre-eclamptic groups were further sub-stratified 
according to HIV status, ie., HIV positive and HIV negative groups (Table 3.1).   
 
Table 3.1 Sample size (percentage) of the six study groups 
Study group Sample size 
(N) 
Percentage of the total study population 
(%) 
Normotensive HIV negative 50 19.61 
Normotensive HIV positive 51 20.00 
EOPE HIV negative 44 17.25 
EOPE HIV positive 37 14.51 
LOPE HIV negative 44 17.25 
LOPE HIV positive 29 11.37 
 
3.2 CLINICAL DATA AND DEMOGRAPHICS 




3.2.1 Maternal age 
The mean maternal age±SD of the total study population was 26.74±6.62 y (Table 3.2). There 
was a significant difference in maternal age between HIV positive and negative groups 
[U=6418.50, p=0.006; Mann-Whitney U test]. Maternal age in the HIV positive group was 
higher (mean rank=141.17) than the HIV negative group (mean rank=116.01). There was no 
significant difference in maternal age between the normotensive and pre-eclamptic groups 
[U=6959.5, p=0.180; Mann-Whitney U test]. There was a significant difference in maternal age 
between the primigravid and multigravid groups [U=2051.00, p<0.001; Mann-Whitney U test]. 
Maternal age in the multigravid group was higher (mean rank=157.44) than the primigravid 
group (mean rank=66.92). 
 
The distribution of maternal age was the same between the normotensive pregnant vs the EOPE 
vs the LOPE groups [χ2(2)=2.415, p=0.299; Kruskal-Wallis test]. There was no significant 













3.2.2 Maternal weight 
The mean maternal weight±SD of the total study population was 75.95±17.61 kg (Table 3.2). 
There was no significant difference of maternal weight between the HIV positive and negative 
groups [U=7842.00, p=0.781; Mann-Whitney U test]. There was no significant difference in 
maternal weight between the normotensive and pre-eclamptic groups [U=6995.50p=0.202; 
Mann-Whitney U test]. There was a significant difference in maternal weight between the 
primigravid and multigravid groups [U=5025.50, p<0.001; Mann-Whitney U test]. Maternal 
weight in the multigravid group was higher (mean rank=140.26) than the primigravid group 
(mean rank=102.12). 
 
The distribution of maternal weight was the same between the normotensive pregnant vs the 
EOPE vs the LOPE groups [χ2(2)=2.058, p=0.357; Kruskal-Wallis test]. There was no significant 






Figure 3.3: Maternal weight (kg) between the primigravid and multigravid groups 
 
3.2.3 Maternal height 
The mean maternal height±SD of the total study population was 157.65±6.49 cm (Table 3.2). 
There was no statistical significance of maternal height between the HIV positive and negative 
groups [t(212)=2.570, p=0.365; Independent samples t-test]. There was no statistical significance 
of maternal height between the normotensive and pre-eclamptic groups [t(212)=-1.428, p=0.702; 
Independent samples t-test], the normotensive pregnant vs the EOPE vs the LOPE groups 




The mean BMI±SD of the total study population was 30.80± 6.67 kg/m2 (Table 3.2). There was 
no significant difference of BMI between the HIV positive and negative groups [U=5449.00, 
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p=0.709; Mann-Whitney U test]. There was no significant difference in BMI between the 
normotensive and pre-eclamptic groups [U=5084.50, p=0.311; Mann-Whitney U test]. There 
was a significant difference in BMI between the primigravid and multigravid groups [U=3511.0, 
p<0.001; Mann-Whitney U test]. BMI in the multigravid group was higher (mean rank=118.10) 
than the primigravid group (mean rank=85.26). 
 
The distribution of BMI was the same between the normotensive pregnant vs the EOPE vs the 
LOPE groups [χ2(2)=2.647, p=0.266; Kruskal-Wallis test]. There was no significant difference in 
BMI across all six study groups [χ2(5)=4.486, p=0.482; Kruskal-Wallis test]. 
 
 





The mean parity±SD of the total study population was 1.02±1.09 (Table 3.2). There was a 
significant difference in parity between HIV positive and negative groups [U=6816.00, p=0.023; 
Mann-Whitney U test]. Parity in the HIV positive group was higher (mean rank=138.74) than the 
HIV negative group (mean rank=118.89). There was no significant difference in parity between 
the normotensive and pre-eclamptic groups [U= 7700.00, p=0.888; Mann-Whitney U test] 
regardless of HIV status. There was a significant difference in parity between the primigravid 
and multigravid groups [U=425.00, p<0.001; Mann-Whitney U test]. Parity in the multigravid 
group was higher (mean rank=168.00) than the primigravid group (mean rank=48.00). 
 
The distribution of parity was the same between the normotensive pregnant vs the EOPE vs the 
LOPE groups [χ2(2)=0.527, p=0.768; Kruskal-Wallis test]. There was no significant difference in 
parity across all six study groups [χ2(5)=5.966, p=0.310; Kruskal-Wallis test]. 
 




The mean gravidity±SD of the total study population was 2.24±1.43 (Table 3.2). There was a 
significant difference in gravidity between HIV positive and negative groups [U=6841.50, 
p=0.028; Mann-Whitney U test]. Gravidity in the HIV positive group was higher (mean 
rank=138.53) than the HIV negative group (mean rank=119.08). There was no significant 
difference in gravidity between the normotensive and pre-eclamptic groups [U=7684.50, 
p=0.867; Mann-Whitney U test]. The distribution of gravidity was the same between the 
normotensive pregnant vs the EOPE vs the LOPE groups [χ2(2)=0.168, p=0.919; Kruskal-Wallis 
test]. There was no significant difference in gravidity across all six study groups [χ2(5)=4.970, 
p=0.420; Kruskal-Wallis test]. 
 




3.2.7 Gestational age 
The mean gestational age±SD of the total study population was 34.51±4.84 weeks (Table 3.2). 
There was no significant difference of gestational age between the HIV positive and negative 
groups [U=7871.00, p=0.976; Mann-Whitney U test]. There was a significant difference in 
gestational age between the normotensive and pre-eclamptic groups [U=2256.50,  p<0.001; 
Mann-Whitney U test]. Gestational age in the normotensive group was higher (mean 
rank=180.21) than the pre-eclamptic group (mean rank=91.75).  
 
The distribution of gestational age was significantly different between the normotensive pregnant 
vs the EOPE vs the LOPE groups [χ2(2)=169.86, p<0.001; Kruskal-Wallis test]. The gestational 
age was higher in the normotensive group (mean rank=180.21) followed by the LOPE group 
(mean rank=147.44) and the EOPE group (mean rank=42.24). There was a significant difference 
in gestational age across all six study groups [χ2(5)=170.146, p<0.001; Kruskal-Wallis test]. 
Gestational age was higher in the normotensive HIV negative group (mean rank=181.77) 
followed by the normotensive HIV positive group (mean rank=178.74), LOPE HIV negative 
(mean rank=150.83), LOPE HIV positive group (mean rank=142.13), EOPE group HIV negative 





Figure 3.7: Gestational age (weeks) across six study groups 
 
3.2.8 Systolic and diastolic pressure 
The mean systolic and diastolic pressure±SD of the total study population was 138.55±26.85 and 
89.04±17.53 mmHg respectively (Table 3.2). There was no statistical significance in systolic 
pressure between the HIV positive and negative groups [t(255)=0.881, p=0.379; Independent 
samples t-test] and in diastolic pressure between the HIV positive and negative groups 
[t(255)=1.087, p=0.278; Independent samples t-test].  
 
However, there was a statistical significance in systolic pressure between the normotensive 
(110.07±10.06 mmHg) and pre-eclamptic groups [157.23±15.63 mmHg; t(255)=-26.88, 
p<0.001; Independent samples t-test] and the normotensive pregnant (110.07±10.06 mmHg) vs 
the EOPE (159.06±14.23 mmHg) vs the LOPE groups [155.19±16.93 mmHg; F(2,252)=365.69, 
p<0.001; ANOVA] and between all six study groups [F(5,249)=146.51, p<0.001; ANOVA] and 
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in diastolic pressure between the normotensive (69.97±7.79 mmHg) and pre-eclamptic groups 
[101.55±8.56 mmHg; t(255), p<0.001; Independent samples t-test] and the normotensive 
(69.97±7.79 mmHg) vs the EOPE (102.7±8.62 mmHg) vs the LOPE groups [100.2±8.36 mmHg; 









Figure 3.9: Diastolic pressure (mmHg) across six study groups 
 
3.2.9 Proteinuria 
There was no statistical significance in the level of urinary protein concentration between the 
HIV positive and negative groups [χ2(3, N=163)=2.55, p=0.466]. However, there was a statistical 
significance in proteinuria between the normotensive and pre-eclamptic groups [χ2(3, 
N=163)=11.63, p=0.009] regardless of HIV status, the normotensive vs the EOPE vs LOPE 
groups [χ2(6, N=163)=14.73, p=0.022] and between all six study groups, [χ2(15, N=163)=27.65, 
p=0.024]. Of the total population 8.6% of normotensive women had a dipstick reading between 
1(71.4%), 2(14.3%), 3(0.0%) and 4(14.3%) whilst 47.9% of the EOPE group had a dipstick 
reading between 1(52.6%), 2(30.8%), 3(15.4%) and 4(1.3%) and LOPE group 1(66.2%), 





3.2.10 CD4+ cell count 
The mean CD4+ cell count±SD of the total study population was 470.75±231.67 cells/mm3 
(Table 3.2). There was no significant difference in CD4+ cell count between the normotensive 
and pre-eclamptic groups [U=551.00, p=0.782; Mann-Whitney U test]. The distribution of CD4+ 
cell count was the same between the normotensive pregnant vs the EOPE vs the LOPE groups 
[χ2(2)=0.313, p=0.855; Kruskal-Wallis test]. There was no significant difference in CD4+ cell 
count across all six study groups [χ2(5)=0.313, p=0.855; Kruskal-Wallis test]. There was no 
significant difference in CD4+ cell count between the primigravid and multigravid groups 
[U=409.50, p=0.444; Mann-Whitney U test].  
 
3.2.11 Residence (Urban or rural)  
There was no significant difference in HIV status of women living either in a rural or urban area 
[χ2(1, N=253)=3.11, p=0.078].  
 
There was a significant difference in a CD4+ cell count <350 and a CD4+ cell count >350 of 
women living in either a rural or urban area, χ2(1, N=119)=6.98, p=0.008. Of the total 
population, 32.8% of women had a CD4+ cell count <350 and 67.2% had a CD4+ cell count 
>350. A total of 45.5% of women with a CD4+ cell count <350 live in a rural area whilst 54.5% 
live in an urban area. A total of 15.6% of women with a CD4+ cell count >350 live in a rural 




There was no significant difference between the normotensive and pre-eclamptic groups of 
women living either in a rural or urban area [χ2(2, N=253)=0.352, p=0.839]. There is no 
significant difference amongst all six study groups [χ2(5, N=253)=4.836, p=0.436].  
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Early onset  
pre-eclamptic  
HIV negative 




Late onset  
pre-eclamptic  
HIV negative 








n 50 51 44 37 44 29 255 
Maternal age (years) 23(18-37) 26(18-40) 26(18-43) 26(19-40) 23(18-40) 29(18-44) 0.058 
Parity 1(0-4) 1(0-3) 1(0-4) 1(0-8) 1(0-4) 1(0-4) 0.310 
Gravidity 2(1-5) 2(1-7) 2(1-7) 2(1-14) 2(1-7) 2(1-5) 0.420 
Gestational age (weeks) 38(31-41) 38(30-41) 30(21-38) 30(20-38) 37(30-40) 37(34-40) <0.001* 
Maternal weight (kg) 72.9(49-143) 70.5(41-111) 78(54.5-124) 73.2(51-125) 72(46-121) 73(54-122) 0.674 
Systolic pressure (mmHg) 111±10.07 109.16±10.06 159.34±13.05 158.73±15.69 153.34±12.74 158.00±21.77 <0.001* 
Diastolic pressure (mmHg) 70.06±8.50 69.88±7.10 103.43±8.63 101.87±8.66 99.66±7.90 101.14±9.08 <0.001* 
Maternal height (cm) 157.92±4.90 155.99±7.62 159.14±7.23 158.60±6.64 156.98±5.89 158.09±5.82 0.286 
BMI (kg/m2) 29.8(18.7-53.2) 29.2(18.2-50.1) 29.9(20.4-43.9) 29.2(20.1-45.9) 31.6(21.2-40.7) 32.0(21.4-44.8) 0.482 
CD4+ cell counts - 400(<100-950) - 358(82-1128) - 558(182-726) 0.855 
Systolic and diastolic pressure and maternal height are expressed as mean±SD and data analysis performed by ANOVA followed by  
Tukey post-test.  
Maternal age, parity, gravidity, gestational age, maternal weight and CD4+ cell counts are expressed as median (range) and data analysis  
performed by Kruskal-Wallis.  
Statistical significance at p<0.05 are highlighted by *. 
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3.3 NEONATAL DATA 
3.3.1 Method of delivery 
Method of delivery was classified as normal vaginal, normal induced, elective caesarean section 
and emergency caesarean section. There was no significant difference in the method of delivery 
between the HIV positive and negative groups [χ2(3, N=203)=01.785, p=0.618], the 
normotensive and pre-eclamptic groups [χ2(3, N=203)=5.139, p=0.162], normotensive pregnant 
vs the EOPE vs the LOPE groups [χ2(6, N=203)=7.142, p=0.308] and all six study groups [χ2(15, 
N=203)=13.515, p=0.563].  
 
3.3.2 Baby outcome (live or stillbirths) 
There was no statistical significance in baby outcome (live or stillborn) between the HIV positive 
and negative groups [χ2(1, N=210)=0.034, p=0.853] and between primigravid and multigravid 
women [χ2(1, N=210)=2.852, p=0.091]. However, there was a significant difference between the 
normotensive and pre-eclamptic groups [χ2(1, N=210)=7.183, p=0.007] and between 
normotensive pregnant vs the EOPE vs the LOPE groups [χ2(2, N=210)=25.909, p<0.001]. Of 
the total population 32.4% were normotensive women and 67.6% were pre-eclamptic (36.6% 
were EOPE and 31.0% were LOPE). There were 100% live births (100%) in the normotensive 
group whilst in the pre-eclamptic group there were only 90.1% live births. A total of 100.0% live 
births were reporteded in the LOPE group, however only 81.8% live births in the EOPE group. 
There also was a relationship between live and stillborn babies across all six study groups [χ2(5, 




3.3.3 Baby weight  
There was no statistical significance in baby weight between the HIV positive and negative 
groups [t(210)=-0.659, p=0.511; Independent samples t-test]. However, baby weight was 
significantly higher in the normotensive group (3.32±0.41 kg) compared to the pre-eclamptic 
group [2.35±0.92 kg, t(210)=8.28; p<0.001; Independent samples t-test]. There was a statistically 
significant difference between groups as determined by one-way ANOVA [F(2,207=113.36, 
p<0.001] with a higher birth weight in the normotensive group (3.32±0.41kg) compared to the 
LOPE group (2.99±0.62kg) and the EOPE group (1.81±0.79kg, p<0.001). There was a 
significant difference in baby weight between all six study groups [F(5,204=45.81, p<0.001; 
ANOVA].  
 






3.3.4 Admission to Neonatal Intensive Care Unit 
There was no significant difference in admission to Neonatal Intensive Care Unit (NICU) 
between the HIV positive and negative groups [χ2(1, N=192)=1.073, p=0.300]. However, there 
was a significant difference in admission of neonates to the NICU between the normotensive and 
pre-eclamptic groups [χ2(1, N=192)=25.254, p<0.001]. Only 8.6% of neonates were admitted to 
NICU in the normotensive group compared to 91.4% in the pre-eclamptic group.  
 
There was a significant difference in admission of neonates to the NICU between the 
normotensive pregnant vs the EOPE group vs the LOPE groups [χ2(2, N=192)=66.94, p<0.001]. 
A total of 74.6% of neonates where admitted to NICU from the EOPE group compared to 19.0% 
in the LOPE group and 8.6% in the normotensive group. There was a significant difference in 
admission of neonates to the NICU between the normotensive HIV negative (5.2%) vs 
normotensive HIV positive (3.4%) vs EOPE HIV negative (41.4%) vs EOPE HIV positive 






Figure 3.11: No. of babies admitted to NICU across pregnancy types  
 
3.3.5 Gender of the baby 
A chi-square test was performed and no relationship was found between the gender of the baby 
(male or female) and HIV status of the mother [χ2(1, N=206)=0.051 p=0.821] and also between 
the normotensive vs pre-eclamptic group [χ2(1, N=206)=3.49 p=0.062]. This study, however 
found a relationship between the gender of the baby and whether the women were primigravid or 
multigravida [χ2(1, N=206)=4.79 p=0.029] and normotensive or EOPE or LOPE groups [χ2(2, 
N=206)=7.12 p=0.028]. Of the total population 35.9% were primigravid whilst 64.1% were 
multigravid. A total of 43.2% of primigravid women had female babies whilst 56.8% had male 
babies. A total of 59.1% of multigravid women had female babies and 40.9% had male babies. 
Of the total population 32.0% were normotensive women, 36.4% were EOPE and 31.6% were 
LOPE. A total of 43.9% normotensive women had female babies whilst 56.1% had male babies, 
65.3% of the EOPE group had female babies whilst 34.7% had male babies and 49.2% of the 
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LOPE group had females babies and 50.8% males babies. There was no difference in the gender 
of the baby across the six study groups [χ2(5, N=206)=8.69, p=0.122]. 
 
 






Figure 3.13: Gender of babies (male or female) across pregnancy groups 
 
3.4 LABORATORY DATA 
The laboratory data for all six study groups are shown in Table 3.3.   
 
3.4.1 Haemoglobin 
The mean haemoglobin±SD of the total study population was 10.71±1.40 g/dL. There was no 
statistical significance in haemoglobin level between the HIV positive and negative groups 
[t(183)=0.579, p=0.563; Independent samples t-test] and between the normotensive and pre-
eclamptic groups [t(183)=-0.280, p=0.780; Independent samples t-test]. Also, there was no 
significant difference in haemoglobin between the normotensive pregnant vs the EOPE vs the 
LOPE groups [F(2,182=0.992, p=0.373; ANOVA] and  across all six study groups 





The mean platelet±SD of the total study population was 210.27±62.50 109/L. There was no 
significant difference in platelets between HIV positive and negative groups [t(161)=-1.010, 
p=0.314; Independent samples t-test] and between the normotensive and pre-eclamptic groups 
[t(161)=1.866, p=0.064; Independent samples t-test]. Also, there was no significant difference in 
platelets between the normotensive pregnant vs the EOPE vs the LOPE groups [F(2,160=1.731, 
p=0.180; ANOVA) and across all six study groups [F(5,157=0.850, p=0.516; ANOVA].  
 
3.4.3 Urea 
The mean urea±SD of the total study population was 2.61±1.37 mmol/L. There was no statistical 
significance in urea concentration between the HIV positive and negative groups [U=1486.00, 
p=0.319; Mann-Whitney U test] and between the normotensive and pre-eclamptic groups 
[U=106.00, p=0.072; Mann-Whitney U test].  
 
The distribution of urea was significantly different between the normotensive pregnant vs the 
EOPE vs the LOPE groups [ χ2(2)=8.567, p=0.014; Kruskal-Wallis test]. Urea was higher in the 
EOPE group (mean rank=66.27) followed by the LOPE group (mean rank=51.35) and the 
normotensive group (mean rank=29.00). There was also a significant difference in urea across all 




Figure 3.14: Urea (mmol/L) across all six study groups 
 
3.4.4 Creatinine 
The mean creatinine±SD of the total study population was 50.27±15.23 µmol/L. There was no 
statistical significance in creatinine between the HIV positive and negative groups [U=1560.50, 
p=0.831; Mann-Whitney U test] and between the normotensive and pre-eclamptic groups 
[U=161.00, p=0.915; Mann-Whitney U test].  
 
The distribution of creatinine was not significantly different between the normotensive pregnant 
vs the EOPE vs the LOPE groups [χ2(2)=0.619, p=0.929; Kruskal-Wallis test] and  across all six 






3.4.5 Alanine aminotransferase 
The mean alanine aminotransferase (ALT)±SD of the total study population was 19.69±9.74 
U/L. There was a statistical significance in ALT between the HIV positive and negative groups 
[U=606.50, p=0.008; Mann-Whitney U test] with higher levels in the HIV positive group (mean 
rank=51.54) compared to the HIV negative group (mean rank=37.14). There was no significant 
difference in ALT between the normotensive and pre-eclamptic groups [U=30.50, p=0.140; 
Mann-Whitney U test].  
 
The distribution of ALT was the same between the normotensive pregnant vs the EOPE vs the 
LOPE groups [χ2(2)=2.614, p=0.271; Kruskal-Wallis test] and across all six study groups 
[χ2(5)=10.577, p=0.060; Kruskal-Wallis test].  
 
 




3.4.6 Aspartate aminotransferase 
The mean aspartate aminotransferase (AST)±SD of the total study population was 25.79±9.60 
U/L. There was no statistical significance in AST between the HIV positive and negative groups 
[U=317.50, p=0.123; Mann-Whitney U test] and between the normotensive and pre-eclamptic 
groups [U=23.00, p=0.189; Mann-Whitney U test]. The distribution of AST was the same 
between the normotensive pregnant vs the EOPE vs the LOPE groups [χ2(2)= 2.396, p=0.302; 
Kruskal-Wallis test] and across all six study groups [χ2(5)=5.818, p=0.324; Kruskal-Wallis test].  
 
3.4.7 Lactate dehydrogenase 
The mean lactate dehydrogenase(LDH)±SD of the total study population was 542.05±210.05 
U/L. There was no statistical significance in LDH between the HIV positive and negative groups 
[t(18)=-0.025, p=0.981; Independent samples t-test] and across all six study groups 
[F(3,16=2.192, p=0.129; ANOVA].  
 
3.4.8 Total bilirubin 
The mean bilirubin±SD of the total study population was 5.74±4.27 µmol/L. There was no 
statistical significance in total bilirubin between the HIV positive and negative groups 
[U=732.50, p=0.102; Mann-Whitney U test] and between the normotensive and pre-eclamptic 
groups [U=50.50, p=0.370; Mann-Whitney U test]. The distribution of total bilirubin was the 
same between the normotensive pregnant vs the EOPE vs the LOPE groups [χ2(2)=1.071, 
p=0.585; Kruskal-Wallis test] and across all six study groups [χ2(5)=8.985, p=0.110; Kruskal-




3.4.9 Total protein 
The mean protein±SD of the total study population was 62.88±9.66 g/L. There was a significant 
difference in total protein between HIV positive and negative groups [t(89)=-4.529, p<0.001; 
Independent samples t-test]. Total protein in the HIV positive group was higher (67.58±9.02) 
than the HIV negative group (59.20±8.55). However, there was no significant difference in total 
protein between the normotensive and pre-eclamptic groups [t(89)=0.386, p=0.700; Independent 
samples t-test] and  between the normotensive pregnant vs the EOPE vs the LOPE groups 
[F(2,88=0.564, p=0.571; ANOVA]. There was a significant difference in total protein across all 






Table 3.3 Blood test results across the six study groups 




Early onset  
pre-eclamptic  
HIV negative 
Early onset  
pre-eclamptic  
HIV positive 
Late onset  
pre-eclamptic  
HIV negative 




n 26 32 41 30 34 22 185 
Haemoglobin (g/dL) 10.74±1.34 10.60±1.24 10.72±1.58 10.38±1.53 10.83±1.44 11.05±1.12 0.638 
Platelets (109/L) 224.94±71.00 228.95±52.82 202.49±70.36 209.60±56.86 200.15±64.03 213.33±51.58 0.516 
Urea (mmol/L) 1.7(1.4-2.8) 0.4(0.4) 2.25(1.2-7.5) 2.4(0.6-10.7) 2.4(1.2-5.2) 2.05(1.2-3.3) 0.028* 
Creatinine (µmol/L) 45(41-65) - 51.0(27-110) 48(30-77) 47(25-91) 48.5(24-68) 0.856 
ALT (U/L) 33(33) 21(21) 15(8-61) 20(9-45) 17(8-32) 21(11-41) 0.060 
AST (U/L) 32(32) 34(34) 21.5(15-55) 24(15-51) 23(15-44) 29(19-40) 0.324 
LDH (U/L) - - 646.57±251.12 652.67±222.00 393.40±145.86 478.00±89.61 0.129 
Total bilirubin (µmol/L) 4(4) 2(2) 5.5(1-14) 3(1-26) 4(1-10) 5(2-12) 0.110 
Total protein (g/L) - - 58.94±9.80 66.27±9.14 59.47±6.51 69.18±9.14 0.002* 
Haemoglobin, platelets, LDH and total protein are expressed as mean±SD and data analysis performed by ANOVA followed by Tukey post-test.  
Urea, creatinine, ALT, AST and total bilirubin are expressed as median (range) and data analysis performed by Kruskal-Wallis.  
Statistical significances at p<0.05are highlighted by *.
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3.5 QUANTIFICATION OF PERIPHERAL NATURAL KILLER CELLS AND THEIR 
RECEPTORS USING MULTICOLOUR FLOW CYTOMETRY 
 
3.5.1 Estimation of peripheral Natural Killer cells 
3.5.1.1 Lymphocytes 
The mean lymphocyte±SD for the total study population was 101377.38±93597.30. There was 
no statistical significance in lymphocyte count between the HIV positive and negative groups 
[U=5194.00, p=0.248; Mann-Whitney U test]. However, a statistically significant difference was 
observed between the normotensive pregnant and pre-eclamptic groups [U=4038.00, p<0.001; 
Mann-Whitney U test] and among all pregnancy types [χ2(2)=14.74, p=0.001; Kruskal-Wallis 
test]. There was an increase in lymphocyte count in the pre-eclamptic (mean rank=121.07) 
compared to the normotensive group (mean rank=90.51) and an increase in the LOPE (mean 
rank=128.77) compared to the EOPE group (mean rank=113.24). A statistically significant 





Figure 3.16: Lymphocytes in all six study groups 
 
3.5.1.2 Natural Killer cells 
The mean Natural Killer cells±SD of the entire study population was 50378.39±64637.25. There 
was no statistical significance in NK (CD3-) cells between the HIV positive and negative groups 
[U=4704.50, p=0.068; Mann-Whitney U test]. A statistically significant difference was observed 
in NK cells in the normotensive pregnant and pre-eclamptic groups [U=4284.50, p=0.008; 
Mann-Whitney U test] and among all pregnancy types [χ2(2)=7.34, p=0.026; Kruskal-Wallis 
test]. There was an increase in NK cells in the pre-eclamptic group (mean rank=115.56) 
compared to the normotensive group (mean rank=93.08) and an increase in the EOPE (mean 
rank=118.30) compared to the LOPE group (mean rank=112.92). A statistically significant 





Figure 3.17: Natural Killer (CD3-) cells in all six study groups 
 
3.5.1.3 Peripheral Natural Killer cells 
The mean peripheral Natural Killer cells±SD of the total study population was 1945.62±3140.17. 
There was a statistically significant difference in peripheral NK (CD56dimCD16+) cells between 
the HIV positive and negative groups [U=4450.00, p=0.021; Mann-Whitney U test]. Peripheral 
NK cells were higher in the HIV negative (mean rank=114.41) compared to HIV positive group 
(mean rank=95.13). There also was a significant difference between the normotensive pregnant 
and pre-eclamptic groups [U=4311.50, p=0.012; Mann-Whitney U test] and among all 
pregnancy types [χ2(2)=7.40, p=0.025 Kruskal-Wallis test].  There was an increase in peripheral 
NK cells in the pre-eclamptic group (mean rank=114.51) compared to the normotensive group 
(mean rank=93.37) and an increase in the LOPE (mean rank=120.33) compared to the EOPE 
group (mean rank=108.59). A statistically significant difference was also observed across all six 












3.5.2 Estimation of peripheral Natural Killer cell receptors (CD69, CD94, NKG2A, NKG2C 
and NKG2D) 
3.5.2.1 CD69  
The mean CD69±SD of the total study population was 500.70±1167.12. There was a statistical 
significant difference in CD69 receptor between the HIV positive and negative groups 
[U=4496.50, p=0.028; Mann-Whitney U test]. There was a decrease in CD69 in the HIV positive 
(mean rank=95.58) compared to the negative (mean rank=113.98) group. Also, a statistically 
significant difference was observed in CD69 in the normotensive pregnant and pre-eclamptic 
groups [U=4454.00, p=0.029; Mann-Whitney U test] and among all pregnancy types 
[χ2(2)=6.34, p=0.042 Kruskal-Wallis test]. There was an increase in CD69 in the pre-eclamptic 
group (mean rank=113.27) compared to the normotensive group (mean rank=94.88) and an 
increase in the LOPE (mean rank=120.24) compared to the EOPE group (mean rank=106.18). 
No difference among all six study groups [χ2(5)=10.83, p=0.055; Kruskal-Wallis test]. 
 






Figure 3.21: CD69 receptor across pregnancy groups 
 
3.5.2.2 CD94 
The mean CD94±SD of the total study population was 983.26±2584.25. There was a statistical 
significant difference in CD94 receptor between the HIV positive and negative groups 
[U=4463.50, p=0.030; Mann-Whitney U test], between the normotensive pregnant and pre-
eclamptic groups (U=4255.00, p=0.011; Mann-Whitney U test), among all pregnancy types 
[χ2(2)=6.41, p=0.041 Kruskal-Wallis test] and all six study groups [χ2(5)=11.31, p=0.046; 
Kruskal-Wallis test]. There was an increase in CD94 in the pre-eclamptic group (mean 
rank=114.00) compared to the normotensive group (mean rank=92.75) and an increase in the 














3.5.2.3 NKG2A  
The mean NKG2A±SD of the total study population was 450.59±911.10. There was a statistical 
significant difference in NKG2A receptor between the HIV positive and negative groups 
[U=4308.00, p=0.012; Mann-Whitney U test]. There was no significant difference between the 
normotensive pregnant and pre-eclamptic groups [U=4809, p=0.212; Mann-Whitney U test] 
however, there was a significant difference among all pregnancy types [χ2(2)=4.62,  p=0.041 
Kruskal-Wallis test] with an increase in the LOPE group (mean rank=112.03) compared to the 
normotensive (mean rank=110.29) and EOPE (mean rank=87.39) groups and across all  six study 
groups [χ2(5)=12.60, p=0.027; Kruskal-Wallis test]. 
 









The mean NKG2C±SD of the total study population was 709.23±1953.26. There was no 
statistical significance in NKG2C receptor between the HIV positive and negative groups 
[U=4740.50, p=0.126; Mann-Whitney U test], between the normotensive pregnant and pre-
eclamptic groups [U=5273.00, p=0.863; Mann-Whitney U test], among all pregnancy types 




The mean NKG2D±SD of the total study population was 1312.30±1876.93. There was no 
statistical significance in NKG2D receptor between the HIV positive and negative groups 
[U=4540.50, p=0.047; Mann-Whitney U test], between the normotensive pregnant and pre-
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eclamptic groups (U=4575.50, p=0.074; Mann-Whitney U test), among all pregnancy types 




Table 3.4 Natural Killer cells and their receptors across the six study groups 




Early onset  
pre-eclamptic  
HIV negative 
Early onset  
pre-eclamptic  
HIV positive 
Late onset  
pre-eclamptic  
HIV negative 































CD56dimCD16+ 484.50(8-9576) 747.50(5-8628) 767(11.81-11878) 431(1-31059) 1135(36-13913) 995(1-6661) 0.016* 
CD94 146(0-8741) 188(0-3862) 502(0-11706) 176(1-29137) 310(14-9657) 215(0-4296) 0.046* 
CD69 19.5(0-9323) 49(0-6959) 71(0-2420) 43.5(0-1454) 97(0-4657) 66(0-2687) 0.055 
NKG2A 48(0-3982) 225.5(0-4075) 16(0-3909) 22(0-5357) 227(0-6703) 21(0-2255) 0.027* 
NKG2C 93(6902) 179(0-1978) 106(0-8677) 26(0-22578) 222(0-5210) 57(0-2684) 0.392 
NKG2D 277(0-9229) 669(3-7037) 530.5(0-11722) 329(0-29661) 762(21-13693) 357(0-4714) 0.152 
Natural Killer cells and their receptors are expressed as median (range) and data analysis performed by Kruskal-Wallis.  
Statistical significances at p<0.05are highlighted by *. 
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3.6 QUANTIFICATION OF TH1 AND TH2 MATERNAL SERUM CYTOKINE LEVELS 
The mean± SD maternal serum Th1 (IL-2, IL-12(70), IFN-γ, TNF-α and GM-CSF) and Th2 (IL-
4, IL-5, IL-10 and IL-13) cytokine levels of all 6 study groups are outlined in Table 2. There 
were no significant differences in maternal serum Th1 (IL-2, p=0.175; IL-12(70),  p=0.923; IFN-
γ, p=0.860; TNF-α, p=0.924 and GM-CSF, p=0.775) and Th2 (IL-4, p=502; IL-5, p=0.420; IL-
10, p=0.795 and IL-13, p=0.177) cytokine levels between the HIV positive and negative groups. 
 
The Kruskal-Wallis test showed that the distribution of Th1 and Th2 cytokines were the same for 
all pregnancy groups (normotensive, early and late onset pre-eclampsia) and across all six study 
groups (Table 3). Although there was an increase in Th1 (IL-2, IFN-γ and GM-CSF, TNF-α) and 
Th2 (IL-13) cytokine levels and a decrease in Th1 (IL12p70) and Th2 (IL-4, IL-5 and IL-10) 
cytokine levels in normotensive patients compared to the pre-eclamptic group, these differences 
were not significant. Also, there was a decrease in Th1 (IL-2, IFN-γ, and GM-CSF) and Th2 (IL-
4 and IL-5) cytokine levels with concurrent increase in Th1 (IL-12p70 and TNF-α) and Th2 (IL-
10 and IL-13) cytokine levels in the early onset compared to the late onset pre-eclamptic group, 
these differences were also not significant. 
 
However, GM-CSF levels were significantly different [χ2(5)=12.03, p=0.034; Kruskal-Wallis 




Table 3.5 Th1/Th2 maternal serum levels (pg/ml) across all six study groups 
 Normotensive pregnant  EOPE LOPE   
(pg/ml) HIV negative  HIV positive  HIV negative  HIV positive  HIV negative  HIV positive  Study population p-Value  
n 30 30 24 26 35 25 170  





















































































































































Th1 and Th2 cytokines are expressed as median (range) and data analysis performed by Kruskal-Wallis.  





Figure 3.26: GM-CSF (pg/ml) maternal serum cytokine levels in all six study groups 
 
3.6.1 Correlation between Th1 and Th2 maternal serum cytokines in pregnancy groups 
Th1 and Th2 cytokines increased simultaneously in the normotensive group (p<0.001) except IL-
13 which increased only with an increase in Th2 cytokines, IL-4 (p=0.004, r=0.454) and IL-10 
(p<0.001, r=0.365). Th1 and Th2 cytokines increased concurrently in the EOPE group. There 
was an increase in Th1 and Th2 cytokines (p<0.001) except IL-13 which did not increase or 
decrease with the Th1 cytokines, GM-CSF (p=0.088, r=0.246) and IL-2 (p=0.334, r=0.141) in 


















3.6.2 Correlation between NK cell receptor expression and Th1/Th2 maternal serum 
cytokines within pregnancy groups 
In the normotensive group, NK cells decreased simultaneously with TNF-α (p=0.013, r=-0.332) 
and IL-10 (p=0.046, r=-0.270). CD69 expression decreased concurrently with all Th1 cytokines. 
Significant correlation between CD69 and the Th2 cytokines, IL-5 (p=0.008, r=-0.355) and IL-
10 (p=0.048, r=-0.268) was found. Only the significant correlations in the EOPE and LOPE 
groups are shown in Tables 3.6 and 3.7 respectively.  
 
Table 3.6 Correlation between NK cell receptor expression and Th1/Th2 maternal serum 
cytokines within the EOPE group 
NK cell receptor 
expression 
Th1/Th2 cytokine p-Value Coefficient of 
correlation (r) 
pNK cells IL-5 0.036* 0.297 
CD94 IL-12(p70) 0.017* 0.337 
CD94 IFN-γ 0.004* 0.403 
CD94 TNF-α 0.003* 0.413 
CD94 GM-CSF 0.002* 0.421 
CD94 IL-4 0.027* 0.313 
CD94 IL-5 0.001* 0.453 
CD94 IL-13 0.013* 0.350 
NKG2A IFN-γ 0.020* 0.329 
NKG2C IL-5 0.022* 0.324 
NKG2D IL-12(p70) 0.040* 0.291 
NKG2D IFN-γ 0.007* 0.378 
NKG2D TNF- α 0.025* 0.316 
NKG2D GM-CSF 0.008* 0.369 
NKG2D IL-5 0.003* 0.408 




Table 3.7 Correlation between NK cell receptor expression and Th1/Th2 maternal serum 
cytokines within the LOPE group 
NK cell receptor 
expression 
Th1/Th2 cytokine p-Value Coefficient of 
correlation (r) 
CD69 IFN-γ 0.011* -0.393 
CD69 TNF-α 0.016* -0.376 
CD69 GM-CSF 0.006* -0.418 
CD69 IL-5 0.029* -0.341 
CD94 IL-12(p70) 0.003* 0.454 
CD94 IFN-γ 0.013* 0.383 
CD94 TNF- α 0.018* 0.368 
CD94 GM-CSF 0.012* 0.388 
CD94 IL-5 0.011* 0.394 
CD94 IL-10 0.048* 0.311 
NKG2A IL-12(p70) 0.030* 0.340 
NKG2D IL-5 0.048* 0.311 









4.1 Introduction – Immune response in HIV associated pre-eclampsia 
Sub-Saharan Africa remains the epicenter of the global HIV pandemic. With the increased 
accessibility to antiretroviral treatment in South Africa there has been a decrease from 40.5% 
(2008-2010) to 34.7% (2011-2013) of maternal deaths attributable to non-pregnancy related 
infections (mostly HIV-related) (Department of Health, Saving Mothers Reported, 2015). The 
other two leading causes of maternal deaths in South Africa are obstretric haemorrhage (15.8%) 
and hypertensive disorders of pregnancy (14.8%) of which 54.2% is attributable to pre-eclampsia 
eclampsia and eclampsia (Department of Health, Saving Mothers Reported, 2015). This deadly 
trio accounts for two thirds of maternal mortality in South Africa, 65% of which could be 
preventable and mostly due to inadequate access to healthcare and lack of trained health care 
professionals. (Department of Health, Saving Mothers Reported, 2015). Furthermore, KwaZulu-
Natal accounts for the highest maternal deaths (22.0%) compared to the other provinces in South 
Africa with 42.5% due to non-pregnancy related infections (mostly HIV-related) and 8.3% to 
pre-eclampsia. This deadly duo therefore warrants investigation and is the focus of our study.  
 
 The pathology and etiology of pre-eclampsia is not fully understood. In the first trimester, 
trophoblast cells invade the myometrium and create the maternal-foetal interface called the 
decidua. Trophoblasts modify the wall of the spiral artery, converting them to large, low 
resistance sinusoids thus allowing an adequate blood supply to the placenta and the growing 
fetus (Bachmayer et al., 2006). Pre-eclampsia occurs when trophoblast migration is deficient and 
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there is failure of the physiological conversion of the myometrial spiral arteries (Walker, 2011). 
Blood flow to the placenta is reduced, hence nutrient and oxygen transfer across the placenta 
limits foetal growth. Trophoblast cell debris that is released into the maternal circulation induces 
an inflammatory response in the second trimester of pregnancy (Bachmayer et al., 2006). This 
explains the hypertension, oedema and proteinuria which are characteristically associated with 
this disease. The invading trophoblast, maternal immunological cells and Natural Killer cells 
play an important role in normal pregnancy development (Walker, 2011).  
 
Natural Killer (NK) cells target viral and tumour cells (Vacca et al., 2013) and play an important 
role in ensuring reproductive success (Fukui et al., 2011). Abnormalities in NK cell response 
amongst other immune responses may cause placental dysfunction and resultant hypertension 
and high levels of proteinuria (Cerdeira and Karumanchi, 2012). There are two types of NK cells 
namely, uterine and peripheral NK cells. Uterine NK cells constitute 70-90% of all blood 
lymphocytes (Fukui et al., 2011). In early pregnancy NK cells within the decidua are known to 
play a role in placentation, angiogenesis and regulation of trophoblast invasion (Bachmayer et 
al., 2009). Peripheral NK cells constitute 5-10% of all blood lymphocytes (Fukui et al., 2011). 
NK cells occur either as CD56bright CD16- or CD56dim CD16+. The former are the major pro-
inflammatory cytokine producers, are less cytotoxic and found mainly in the decidua whilst the 
latter are cytotoxic and found mainly in peripheral blood (Bachmayer et al., 2009; Fukui et al., 
2011). Studies have shown the usefulness of uterine NK cells to ensure successful pregnancies 
however, the function of peripheral NK cells in pregnancy and moreover in pathological 
pregnancies such as pre-eclampsia are not well known (Fukui et al., 2011).   
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The activity of NK cells are regulated by inhibitory and activating receptors. CD56dimCD16bright 
NK cells express the inhibitory killer cell immunoglobulin-like receptors (KIR) which are found 
predominately in the peripheral blood. CD56bright CD16dim lack KIR expression but express high 
levels of the activating CD94/NKG2 receptors which are found in the peripheral tissues. 
CD94/NKG2 receptors include the inhibitory receptor CD94/NKG2A and the stimulatory 
receptors CD94/NKG2C and NKG2D (Bachmayer et al., 2009). These receptors play an 
important role in the formation of the decidua and placenta (Bachmayer et al., 2006).  
 
NK cells are triggered by cytokines, IL-12, IL-15 and IL-18. Once activated NK cells express 
CD69 which activate IFN-ƴ production that contribute to a type I response in the circulation in 
pre-eclampsia (Bachmayer et al., 2009). In healthy non-pregnant women there is a balance 
between the Th1 and Th2 response (Laresgoiti-Servitje et al., 2010). However, in successful 
normal pregnancy there is a shift from the Th1 to a Th2 immune response (Laresgoiti-Servitje et 
al., 2010). In pathological pregnancies such as pre-eclampsia, spontaneous miscarriages and 
intrauterine growth restriction (IUGR), the regulation of the maternal immune system is further 
altered and the shift to a Th2 immune response does not occur (Laresgoiti-Servitje et al., 2010). 
Wegmann et al. (1993) proposed that the placenta is a Th2 organ that stimulates the production 
of Th2 cytokines in the maternal immune system. When the development of the placenta is 
abnormal, the maternal immune system responds by producing Th1 cytokines. Transforming 
growth factor-β cytokines surge thereby retarding cytotrohophoblast migration (Laresgoiti-
Servitje et al., 2010; Fukai et al., 2011). Moreover, syncytiotrophoblast debris is increased in pre-
eclamptic maternal circulation due to an ischemic placenta thereby triggering the Th1 response 




Although the role of NK cells is to destroy viral cells, HIV has the ability to suppress the 
function of NK cells. The role of NK cells in HIV is well documented but their role in HIV 
associated pre-eclampsia has produced conflicting results(Conde-Agudelo et al., 2008). Some 
studies reported that untreated HIV infection lowers the rate of preeclampsia whilst treated HIV 
infection restores the rate of pre-eclampsia. Other studies reported that there is no difference in 
treated and untreated HIV infection in preeclampsia (Mattar et al., 2004). In an attempt to 
elucidate the influence of HIV on NK cells in pre-eclampsia this study used multicolour flow 
cytometry to compare peripheral NK cells in HIV positive and negative normotensive, early and  
late onset pre-eclamptic women.  
 
In HIV infected patients, there is a decrease in Th1 cytokines with a concurrent increase in Th2 
cytokine production (Clerichi and Shearer, 1993). Th2 cytokines respond to extracellular 
infection and are known to suppress the immune system (Kalkunte et al., 2011). However, there 
are conflicting results on the secretion of cytokines in pre-eclampsia and HIV (Chatterjee et al., 
2011). In an attempt to understand the maternal immune response in HIV associated pre-
eclampsia, our study used multiplex enzyme-linked immunosorbent assay (ELISA) to compare 
the maternal serum levels of Th1 and Th2 cytokines in HIV positive and negative pre-eclamptic 
(early and late onset ) with normotensive pregnant Black South Africans. 
 
Other studies have looked at the maternal immune response (both NK cells and Th1 and Th2 
cytokines) in HIV and pre-eclampsia in isolation and further have not sub-stratified the pre-
eclamptic group into early and late onset. In view of the high prevalence of pre-eclampsia 
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superimposed with HIV in South Africa, this novel study will attempt to determine the role of 
the maternal immune response in HIV associated pre-eclampsia.   
 
4.2 Clinical data and demographics 
4.2.1 Maternal age 
Our study did not find a significant difference in maternal age between the normotensive and 
pre-eclamptic groups, however other studies have found that older women are at a higher risk of 
developing pre-eclampsia than younger women (Tessema et al., 2015; Gupta and Chari, 2015). 
Older women are more prone to cardiovascular disease as the blood vessels may lose compliance 
and also the haemodynamic adaptation during pregnancy becomes more difficult (Tessema et al., 
2015). However, young maternal age has also been identified as a risk factor for preterm birth, 
low foetal birth weight and foetal growth restriction (Gold et al., 2014). The Tenth interim 
reported on Confidential Enquiries into Maternal Deaths in South Africa, 2011 and 2012 
reporteded that teenagers are at increased risk of dying due to complications of hypertension in 
pregnancy (Fawcus et al., 2013). This may be due to limited sperm exposure which could lead to 
an inflammatory response to the paternal antigens thereby eliciting a Th1 immune response 
which is associated with poor placental development and foetal growth (Dekker and Robillard, 
2007). 
 
Maternal age in the HIV positive group was significantly higher (p=0.006) than the HIV 
negative group. In 2012, South Africa reporteded that non-pregnancy related infections (mostly 
HIV related) were highest between 25-40 years of age (Fawcus  et al., 2013). Younger women 




4.2.2 Maternal weight and BMI 
Gupta and Chari, (2015) support our findings of no significant differences in maternal weight 
and BMI in pre-eclampsia compared to normotensive pregnancy. Other studies have found BMI 
to be a risk factor for pre-eclampsia development in HIV uninfected pregnant women (Machado 
et al., 2014). However, obesity is a huge problem globally (Roberts et al., 2011) and in South 
Africa 42.0% of women are overweight which is the highest in Sub-Saharan Africa and third 
highest in the world (Ng et al., 2014). Overweight and obesity are known risk factors of pre-
eclampsia. Futhermore, overweight has been associated with oxidative stress consisting of an 
imbalance of lipid metabolism and an inflammatory state that is also associated with pre-
eclampsia. However, during pregnancy especially in the third trimester overweight may be due 
to fluid retention (Machado et al., 2014). 
 
4.2.3 Parity and gravidity 
Parity (no. of live births, p=0.023) and gravidity (no of pregnancies, p=0.028) were higher in the 
HIV positive group than the HIV negative group. Multiple pregnancies may increase the risk of 
HIV transmission. Multigravid women with pre-eclampsia in a prior pregnancy have an 
increased risk of developing pre-eclampsia in a subsequent pregnancy (Roberts et al., 2011; 
Machado et al., 2014). 
 
4.2.4 CD4+ cell count and ARV treatment 
The role of HIV-infection in the development of pre-eclampsia is controversial. Hall et al., 2014 
and Kalumba et al. (2012) found that pre-eclampsia was less common in HIV positive women. 
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Wimalasundera et al., (2002) found a lower rate of pre-eclampsia among untreated HIV positive 
women when compared to negative women or HIV positive on treatment. Several studies found 
no significant difference in pre-eclampsia between HIV negative and infected women on 
treatment. Being on HAART at conception was associated with a 2.3 times increased risk of 
developing pre-eclampsia during pregnancy (Machado et al., 2014). 
 
In our study all pregnant women were on ARV treatment, either HAART or Fixed Dose 
Combination (FDC). Our study was limited as we did not include an HIV positive ARV 
treatment naïve group so as to determine the effect of ARV treatment in HIV associated pre-
eclampsia. Of the total population, 32.8% of women had a CD4+ cell count <350 cells/mm3 and 
67.2% had a CD4+ cell count >350 cells/mm3. Our study was further limited by missing CD4+ 
cell count data (41% of the total HIV population), hence the effect of CD4+ count on pre-
eclampsia could not be accurately determined. A total of 45.5% of women with a CD4+ cell 
count <350 cells/mm3 live in a rural area whilst 54.5% live in an urban area. A total of 15.6% of 
women with a CD4+ cell count >350 cells/mm3 live in a rural area and 84.4% live in an urban 
area (p=0.008). This shows that access to ARV treatment may be limited in the rural area 
compared to the urban area. Access may also be limited by cost of transport from a rural area to 
hospitals and clinics in an urban area.  
 
4.3 Neonatal data 
4.3.1 Method of delivery 
Our study found no significant differences in method of delivery (normal vaginal, normal 
induced, elective caesarean section and emergency caesarean section) between HIV positive and 
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negative groups (p=0.618) as well as amongst pregnancy types (p=0.308). Increasing rates of 
early elective delivery either labour induction or caesarean section before 40 weeks gestation has 
been reporteded internationally. Changes in elective delivery are changing the distribution of 
gestational age at or near term (Roberts et al., 2011). Also, the prevention of mother to child 
transmission (PMTCT) of HIV has progressed from recommending caesarean section (Machado 
et al., 2014). 
 
4.3.2 Gestational age, baby weight and baby outcomes (live/stillbirths)  
In pre-eclampsia a failure of the physiological transformation of uterine arteries results in a 
reduced placental supply of oxygen and nutrients (Nakimuli et al., 2014). The only known 
treatment for pre-eclampsia is delivery of the placenta which leads to premature delivery and 
adverse effects on neonatal outcomes such as small for gestational age for delivery, lower birth 
weight and an increased risk of stillbirths (Wang et al., 2009; Backes et al., 2011). The results of 
our study confirms the previous study as gestational age (p=0.001) and baby weight (p=0.001) 
were significantly lower in the pre-eclamptic compared to the normotensive group, also being 
lower in the early compared to the late onset pre-eclamptic group. Also, 18.2% of stillbirths 
occurred in the early compared to none in the late onset pre-eclamptic and normotensive groups.  
Although there were no significant differences of gestational age (p=0.976), baby weight 
(p=0.511), baby outcome (live or stillborn; p=0.853) and admission to NICU (p=0.300) between 
the HIV positive and negative groups irrespective of pregnancy status. HIV infection has been 
associated with adverse birth outcomes (Chen et al., 2012) such as preterm delivery, small 
gestational age infants and stillbirths which were more common in HIV positive than negative 
women. Arechavaleta-Velascoet et al. (2006) showed that adeno-associated virus-2 infection can 
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induce placental dysfunction by inhibiting invasion of extravillous trophoblast cells and by 
causing trophoblast cell death (Conde-Agudelo et al., 2008). Further studies should determine 
the risk of ARV treatment on placental development and neonatal outcome. 
 
4.3.3 Admission to NICU 
A total of 74.6% of neonates where admitted to NICU from the EOPE group compared to 19.0% 
in the LOPE group and 8.6% in the normotensive group. Duhig and Shennan, (2015) and Ilekis, 
et al., (2007) also reporteded an increased risk of stillbirths in EOPE. Early diagnosis of pre-
eclampsia may be possible if pregnant women seek antenatal care early in pregnancy (Tessema 
et al., 2015). It has also been found that women diagnosed with EOPE also are at a greater risk of 







4.4 Laboratory data 
4.4.1 Haemoglobin 
Our study found no significant differences in haemoglobin concentration between HIV positive 
and negative groups (p=0.563) and the pre-eclamptic and normotensive groups (p=0.780). 
Aghamohammadi, et al. (2011) showed that high haemoglobin levels in the first trimester 
increases the risk of pregnancy induced hypertension. Increased concentrations of haemoglobin 
may cause vasoconstriction and abnormal endothelial cell function. Due to vasoconstriction the 
number of red blood cells increases but blood volume does not increase in pre-eclampsia which 
results in a limited supply of oxygen and nutrients to the growing fetus (Aghamohammadi et al., 
2011). This in turn results in a small gestational age baby and lower birth weight. (Machado et 
al., 2014).  
 
4.4.2 Platelets 
Our study found no significant difference in platelets between the normotensive and pre-
eclamptic groups (p=0.064). In normal pregnancy there is an increase in platelet aggregation but 
decrease in circulation with gestation. In pre-eclampsia due to the failure of cytotrophoblast 
invasion into maternal spiral arteries and subsequent dysfunction of the endothelial cells, results 
in increased platelets in uteroplacental circulation and decreased platelets in maternal circulation 
early in pregnancy (Juan et al., 2011).  
 
4.4.3 Urea 
Serum urea concentration was higher in the early onset pre-eclamptic group followed by the late 
onset pre-eclamptic group and the normotensive group (p=0.014). There also was a significant 
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difference in urea across all six study groups (p=0.028). Jumaah (2012) reporteded similar 
findings of higher urea in the pre-eclamptic compared to the normotensive group. Pre-eclampsia 
is associated with renal function abnormalities (Jumaah, 2012). An increased resistance of the 
afferent arterioles reduces blood flow to the kidneys and causes renin to activate the renin 
angiotensin aldosterone system which increases blood pressure and reabsorption of sodium ions 
into the bloodstream. This coupled with a decreased glomerular filtration rate and plasma volume 
contraction contributes to increased amount of urea in the blood (Zar et al., 2011). 
 
4.4.4 Creatinine 
There was no significant difference in creatinine between the HIV positive and negative groups 
(p=0.831), between the normotensive and pre-eclamptic groups (p=0.915), between the 
normotensive pregnant vs the EOPE vs the LOPE groups (p=0.929) and across all six study 
groups (p=0.856). Weerasekera et al., (2003) also showed no difference in creatinine levels in the 
pre-eclamptic compared to the normotensive group. 
 
4.4.5 Alanine transaminase 
There was a significant difference in alanine transaminase (ALT) between the HIV positive and 
negative groups (p=0.008) with higher levels in the HIV positive group compared to the HIV 
negative group. The liver is a site for HIV replication and when the liver is damaged, 






4.4.6 Aspartate aminotransferase 
There was no significant difference in aspartate aminotransferase (AST) between the HIV 
positive and negative groups (p=0.123), between the normotensive and pre-eclamptic groups 
(p=0.189), between the normotensive vs early onset pre-eclamptic vs the late onset pre-eclamptic 
groups (p=0.302) and across all six study groups (p=0.324). Higher levels of the liver enzymes 
AST and ALT were found in early onset pre-eclamptic patients which was associated with a 
higher risk of developing severe pre-eclampsia (Mei-Dan et al., 2013).  
 
4.4.7 Lactate dehydrogenase 
There was no significant difference in LDH between the HIV positive and negative groups 
(p=0.981) and across all six study groups (p=0.129). Higher serum LDH levels were shown in 
HIV positive patients compared to HIV negative patients. LDH plays an important role in 
glucose metabolism and during infection high levels are released. Furthermore HAART has been 
shown to have toxic effects on various organs which further results in an increase in LDH levels 
(Ramana et al., 2013). 
 
4.4.8 Total bilirubin 
There was no significance difference in total bilirubin between the HIV positive and negative 
groups (p=0.102), between the normotensive and pre-eclamptic groups (p=0.370), between the 
normotensive pregnant vs the EOPE vs the LOPE groups (p=0.585) and across all six study 
groups (p=0.110). McDonald et al., (2012) supports our finding of no difference in HIV positive 




4.4.9 Total protein 
Total protein in the HIV positive group was higher (67.58±9.02) than the HIV negative group 
(p<0.001; 59.20±8.55). There was a significant difference in total protein across all six study 
groups (p=0.002). Similar results were reporteded by Sarro et al. (2010). HIV infection induces 
changes in serum proteins such as globulins which occur above the normal range of 21 - 37 g/L 
and decreased albumin levels. Normally albumins are the most abundant protein found in blood 




4.5 Innate immune system – Lymphocytes 
Pre-eclampsia is triggered by placental antigens which results in an exagerated maternal 
inflammatory response. Abnormal levels of immune factors suggest a possible role of the innate 
immune system in particular NK cells which are responsible for the production of cytokines and 
the expression of activating or inhibitory receptors (Bueno-Sánchez et al., 2013).  
 
In our study, there was no significance difference in lymphocytes between the HIV positive and 
negative groups (p=0.133). ARV treatment may have contributed to increasing the lymphocyte 
population to similar levels to that of HIV negative patients. A significant difference was 
observed between the normotensive pregnant and pre-eclamptic groups (p<0.001) and among all 
pregnancy types (p<0.001) and in all six study groups (p<0.001). There was an increase in 
lymphocytes in the pre-eclamptic group compared to the normotensive group and an increase in 
the late onset compared to the early onset pre-eclamptic group. Mosimann et al. (2013) showed a 
significant decrease in the total lymphocyte population from the first to the second trimester 
(p=0.015) and no significant change from the second to the third trimester (p=0.286) in 
normotensive pregnancies. 
 
4.5.1 Natural Killer cells  
NK cells (CD3-) comprise 15% of peripheral blood lymphocytes and provide an immediate 
defense against infection (Acar et al., 2011). It is known that NK cells are reduced in the latter 
stage of HIV infection and in pregnancy (Kane et al., 1996). In our study there was no significant 
difference in NK cells between the HIV positive and negative groups (p=0.198). Our study 
participants may be at various stages of HIV infection and since all HIV positive patients were 
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on ARV treatment this may have played a role in improving the NK cell population. There was a 
significant increase in NK cells in the pre-eclamptic group compared to the normotensive group 
(p<0.001) and an increase in the EOPE to the LOPE groups (p<0.001). This increase may be 
explained by the release of syncytiotrophoblast-derived micro-particles (STBM) from the 
placenta of pre-eclamptic women (Germain et al., 2007). A study that looked at the in vitro 
activated mononuclear cells from mildly pre-eclamptic patients showed a decrease in NK cells 
(van Nieuwenhoven et al., 2008). Bachmayer et al. (2006) showed a lower percentage of NK 
cells at delivery in both the pre-eclamptic and normotensive pregnant groups compared to a non-
pregnant group (p=0.06) whilst Mosimann et al. (2013) reporteded a significant decrease in the 
total NK cell count (p=0.009) from the first to the third trimester of pregnancy. A limitation of 
our study was that we did not evaluate peripheral NK cells across the trimesters of pregnancy.  
 
4.5.2 Peripheral Natural Killer cells 
There are two types of NK cells namely, uterine (CD56brightCD16+) and peripheral 
(CD56dimCD16+) NK cells (Fukui et al., 2011). Uterine NK cells are the major pro-inflammatory 
cytokine producers, are less cytotoxic and found mainly in the decidua whilst the latter are 
cytotoxic, produce less cytokines and found mainly in peripheral blood (Bachmayer et al., 2009 
and Fukui et al., 2011). There was a significant difference in peripheral NK cells between the 
HIV positive and negative groups (p=0.024). Peripheral NK cells were higher in the HIV 
negative group compared to HIV positive group. This is surprising as peripheral NK cells 
possess more cytotoxic properties and would be expected to be present in larger amounts in the 
HIV positive compared to the negative group. However, HIV infection is known to suppress the 
cytotoxic properties of NK cells which may explain these results.  
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There was a significant increase in peripheral NK cells in the pre-eclamptic group (mean 
rank=114.51) compared to the normotensive group (mean rank=93.37; p=0.012) and an increase 
in the LOPE (mean rank=120.33; p=0.025) compared to the EOPE group (mean rank=108.59) 
and across all six study groups (p=0.016). Mosimann et al. (2013) also showed a decrease in 
peripheral NK cells in normotensive pregnancy. Pre-eclampsia is associated with exaggerated 
inflammation and increased production of cytokines (Schumacher, 2014). This study confirms 
this as increased accumulation of peripheral NK cells were observed in pre-eclamptic compared 
to the normotensive pregnancies. However, Bueno-Sánchez et al. (2013) reporteded no 
difference in CD56dim population in the severe pre-eclamptic group compared to the 
normotensive group (p=0.11).  
 
4.5.3 CD69 
CD69, a C-type lectin receptor is an early, nonspecific NK cell activation marker. When NK 
cells are activated upon infection or inflammation there is an increase in the levels of CD69 
(Fogel et al., 2013). However, our study showed a decrease in CD69 in the HIV positive (mean 
rank=95.58) compared to the negative (mean rank=113.98; p=0.343). All patients in our study 
were on ARV treatment which may have played a role in decreasing CD69 in HIV positive 
patients. A significant difference was observed between the normotensive pregnant and pre-
eclamptic groups (p=0.003) and among all pregnancy types (p=0.007). In normal pregnancy 
cytotoxic NK cells are decreased suggesting that activated CD69 expressing NK cells play an 
important role in the control of trophoblast growth and placental development (Mosimann et al., 
2013). However, a conflicting reported by Bachmayer et al. (2006) showed no difference in 
CD69 in the pre-eclamptic compared to the normotensive group. Also a limitation of this study is 




4.5.4 CD94, NKG2A and NKG2C receptors 
CD94/NKG2 receptor is a member of the C-type lectin superfamily which consists of five 
receptors, NKG2A, NKG2C, NKG2D, NKG2E and NKG2F. NKG2A and NKG2B are 
inhibitory receptors which inhibits NK cell function whilst NKG2C and NKG2D are NK cell 
activating receptors (Bachmayer et al., 2009). NKG2A negatively regulates cytotoxic activity 
and Th2 cytokine production and NKG2C triggers NK cell effector functions (Lanier et al., 
1998). IL-12/IL-15 or IFN and IL-10 stimulates an increase in NKG2A which may negatively 
affect NKG2C activity (Bueno-Sánchez et al., 2013). 
 
In our study there was a significant difference in NKG2A between the HIV positive and negative 
groups (p=0.012), among all pregnancy types (p=0.041) and across all six study groups 
(p=0.027). There was no difference in NKG2A between the normotensive pregnant and pre-
eclamptic groups (p=0.212). There was no significant difference in NKG2C (p=0.126) between 
the HIV positive and negative groups, between the normotensive pregnant and pre-eclamptic 
groups (p=0.863), among all pregnancy types (p=0.982) and across all six study groups 
(p=0.392). An increase in NKG2C cells compared to NKG2A cells have been reporteded in HIV 
infected patients  (Bachmayer et al., 2006). Data are conflicting with others studies which have 
shown a significant increase in percentage of NKG2A and NKG2C receptors in severely pre-
eclamptic women compared to normotensive women (Kusumi et al., 2006; Bueno-Sánchez et al., 
2013). Bachmayer et al. (2006) supports our findings of similar percentages of peripheral NK 
cell NKG2A and NKG2C receptors in pre-eclamptic and normotensive pregnant women 
however, higher levels of both receptors were reporteded in pre-eclampsia compared with 
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healthy pregnant women.  
 
Kusumi et al. (2006) found that decidual NK cells express inhibitory NKG2A and activating 
NKG2C cells concurrently to control trophoblast invasion in the developing placenta whereas 
peripheral NK cells express these receptors equally. Inhibitory NK receptors may prevent 
maternal rejection of a fetus and activating NK receptors may also be important because 
trophoblasts never excessively invade into decidua. Thus, the balance of inhibitory and activating 
NK receptors is crucial for the proper growth of trophoblasts in placenta (Yokoyama and Riley, 
2008; Kusumi et al., 2006). The invading trophoblasts have direct contact with maternal 
peripheral lymphocytes hence the expression of activating NKG2C may attack the trophoblasts 
and prevent them from invading maternal vessels in pre-eclampsia (Kusumi et al., 2006). 
 
4.5.5 NKG2D receptor 
There was a significant difference in the stimulatory receptor NKG2D receptor between the HIV 
positive and negative groups (p=0.047). There was no significant difference between the 
normotensive pregnant and pre-eclamptic groups (p=0.074), among all pregnancy types 
(p=0.131) and across all six study groups (p=0.152). Bachmayer et al. (2006) supports our 
finding of similar percentages of peripheral NK cell NKG2D receptor in pre-eclamptic and 
normotensive pregnant women. However, a lower expression of NKG2D was shown in pre-




4.6 Th1 and Th2 maternal immune response 
4.6.1 Th1 and Th2 response in pre-eclampsia 
In pre-eclampsia, abnormal trophoblast invasion and inadequate spiral artery remodeling 
produces a hypoxic microenvironment with resultant increased placental oxidative stress. The 
resulting flux of anti-oxidant and anti-angiogenic balance contributes to systemic endothelial 
dysfunction augmenting the inflammatory response (Kalkunte et al., 2011; Chatterjee et al., 
2011). This leads to the subsequent clinical manifestation of pre-eclampsia (Perez-Sepulveda et 
al., 2014). The abnormal trophoblast invasion may be attributed to the altered maternal immune 
response to the semi allogenic fetus which leads to the production of neutrophils and monocytes 
in the decidua and within peripheral blood. Consequently this stimulates the production of pro-
inflammatory (Th1) cytokines whilst anti-inflammatory (Th2) cytokines are reduced (Bachmayer 
et al., 2006). Our study however, revealed no shift from a Th1 (IL-2, p=0.357; IL-12(70), 
p=0.105; IFN-γ, p=0.086; TNF-α, p=0.091) response to a Th2 (IL-4, p=0.144; IL-5, p=0.188; IL-
10, p=0.446 and IL-13, p=0.334) response across the HIV positive and negative normotensive, 
EOPE and LOPE groups. 
  
This study showed a significant difference in the level of GM-CSF across each of the 6 study 
groups. Granulocyte-macrophage colony-stimulating factor (GM-CSF) levels are elevated in the 
presence of HIV infection as they are responsible for stimulating monocyte derived macrophages 
that fight infection (Le Bouteiller et al., 2011). Chatterjee et al. (2011) showed that the incidence 
of pre-eclampsia is decreased in women with HIV infection. In addition, in normal pregnancy 
there is a shift from the Th1 to the Th2 maternal immune response irrespective of HIV status 
with the Th2 cytokines being dominant in circulation whereas in pre-eclampsia the shift does not 
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occur with the Th1 cytokines being dominant in circulation whilst in HIV infection there is a 
counter shift from the Th1 to the Th2 response with the Th2 cytokines being more prominent. 
Hence in HIV associated pre-eclampsia there could be a counteraction in the Th1 and Th2 









Figure 4.1: Proposed Th1 and Th2 maternal immune response in HIV+ associated pre-eclampsia. 
In normal pregnancy there is a shift from the Th1 to the Th2 maternal immune response with the 
Th2 cytokines being dominant in circulation whereas in pre-eclampsia this shift does not occur 
with the Th1 cytokines dominant in circulation whilst in HIV infection there is a counter shift 
from the Th1 to the Th2 response with the Th2 cytokines more prominent. Hence in HIV+ 
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associated pre-eclampsia there could be a counteraction in the Th1 and Th2 cytokine levels 
hence a neutralization of Th1 and Th2 response. 
 
4.6.2 Th1 immune response in pre-eclampsia 
In our study, IL-12(p70) was slightly decreased in the normotensive compared to the pre-
eclamptic cohort, irrespective of HIV status. Additionally, there was an increase in IL-12 (p70), 
in the EOPE compared to the LOPE group, these differences were also not significant. 
Dysregulated immune activation has been advocated as a contributor to pre-eclampsia and 
HELLP development (Becker, 2004). However, data are conflicting in that Mansouri et al. 
(2007) found an increased IL-12 level in pre-eclamptic women whilst Pinheiro et al. (2013) 
reporteded no difference in IL-12 between the normotensive and pre-eclamptic groups. The 
conflicting reporteds of IL-12 levels may be attributed to variability in gestational age at time 
point of collection of serum in the evolving pre-eclamptic disease etiology. Notably, the kinetics 
of IL-12 production and metabolism are also not fully elucidated. Our study also correlates IFN-
γ increase with IL-12 (p70) elevation in all pregnancy groups (p<0.001). IL-12 promotes IFN-γ 
production for successful implantation and placentation (Bachmayer et al., 2009). 
 
Albeit not significant, our study reporteds an increase in TNF-α levels at term in normotensive 
compared to pre-eclamptic women. Also, we show a trend of increase in TNF-α in the EOPE 
compared to the LOPE group, also non-significant. Many studies support our findings of no 
significant difference in TNF-α levels in pre-eclampsia compared to normotensive pregnancy 
(Becker, 2004; Pinheiro et al., 2013; Szarka et al., 2010). On the other hand, other studies have 
shown elevated levels in pre-eclamptic women (Alanbay et al., 2012). TNF-α is known to 
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promote apoptosis and systemic endothelial dysfunction which leads to oxidative stress 
(Vitoratos et al., 2012). Daher et al. (1999) showed low levels of TNF-α in the first trimester of 
normal pregnancies with an increase in gestational age. The erraticism of TNF-α levels may be 
confounded by gestational ages at < or > 34 weeks in the PE groups. 
 
In a recent study, Kumar et al. (2013) reporteded that the levels of IL-10, TNF-α and IFN-γ 
between 14 and 18 weeks of gestation may act as potential biomarkers in the diagnosis of pre-
eclampsia. However, other studies have reporteded elevated IFN-γ in the pre-eclamptic group 
compared to the normotensive group (Mansouri et al., 2007; Pinheiro et al., 2013). Opposing 
results have been demonstrated by others (Jonsson, 2005; Arriaga-Pizano L et al., 2005). IFN-γ 
is known to play an important role in decidual vascular remodeling and angiogenesis. The 
expression of IFN-γ by trophoblast cells is increased early in normotensive pregnancy and 
gradually decreases as pregnancy progresses (Kumar et al., 2013). Yet again gestational age may 
confound IFN-γ levels. 
 
4.6.3 Th2 immune response in pre-eclampsia 
In our study there was a decrease in IL-4 and IL-10 in normotensive patients compared to the 
pre-eclamptic group, albiet not significant. This Th2 cytokine decline (IL-4 and IL-10) between 
the normotensive and pre-eclamptic groups is similar to the reported by Kumar et al. (2013). 
Also, we reported a decrease in IL-4, and an increase in IL-10 in the EOPE compared to the 
LOPE group irrespective of HIV status, these differences were also not significant. Our results 
were obtained at term gestational ages however; increased IL-4 levels in the second trimester and 
puerperium have been associated with pre-eclampsia development. Pinheiro et al. (2013) showed 
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decreased IL-4 levels in pre-eclampsia compared to the normotensive group. IL-10 plays an 
important role in infection by reducing inflammation and tissue damage (Kalkunte et al., 2011). 
In pregnancy, IL-10 suppresses pro-inflammatory cytokine production at the maternal foetal 
interface, vascular dysfunction, endothelial dysfunction and prevents placental apoptosis 
(Chatterjee et al., 2011). Reduced levels of IL-10 may result in poor placentation and production 
of anti-angiogenic molecules, soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin 
(sEng) (Kalkunte et al., 2011). IL-10 levels decrease in the third trimester compared to the first 
and second trimesters (Kalkunte et al., 2011). Pinheiro et al. (2013) showed increased IL-10 
levels in normotensive compared to the pre-eclamptic group. Limitations to the evaluation of IL-
10 levels include its short half-life, hence it may be impossible to correctly determine the 
production of IL-10 in pre-eclampsia (Pinheiro et al., 2013).  
 
4.6.4 Th1 and Th2 immune response in HIV  
During HIV-1 infection changes in the Th1/Th2 cytokine balance is due to an allergic response 
to viral proteins which up-regulate the production of Th2 cytokines (Becker, 2004). Allergic 
responses and HIV-1 infection are similar in that Th2 cytokines, IL-4 induces the production of 
IgE antibodies which results in the depletion of CD4+ cells thereby preventing the production of 
IFN-γ. Also, IL-5 induces eosinophilia and enhances the replication of HIV in CD4+ 
lymphocytes and IL-13 which also up-regulates IgE production has been shown to reduce viral 
load but also block the production of IL-12 (Becker, 2004; Mikovits et al., 1994). IL-4 further 
prevents the production of Th1 cytokines, IL-2, IL-12 and IFN-γ which are responsible for 
stimulating the production of cytotoxic T cells (CTLs). These responses are different in HIV-1 
infection where the interaction with viral proteins is suppressed by the immune system which 
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prevents the production of CTLs (Becker, 2004). However, Graziosi et al. (1996) found low 
expression of IL-2 and IL-4 in HIV positive non-pregnant patients (Graziosi et al., 1996). This 
study however, demonstrates no difference in Th1 and Th2 cytokines when comparing the HIV 
positive to the negative groups irrespective of pregnancy status. Romagnini et al. 1994 also does 
not support the Th1 to Th2 shift hypothesis proposed by Clerici and Shearer (1993), instead 
suggesting that HIV may prefer Th2 cytokines for replication (Kalkunte et al., 2011; Le 
Bouteiller et al., 2011). 
 
4.6.5 Correlation between NK cell receptor expression and Th1/Th2 maternal serum 
cytokines within pregnancy groups 
NK cells play an important role against pathogens and infection through their cytolytic activity 
and production of pro-inflammatory (Th1) cytokines (Vacca et al., 2013). NK cells also require 
the stimulus of pro-inflammatory cytokines such as IL-2, IL12 and IFN-γ to proliferate. In our 
study we aimed to determine the correlation between peripheral NK cells and their receptors with 
circulating Th1 and Th2 cytokines. In the normotensive pregnant group there was a simultaneous 
decrease in NK cells and IL-10 (p=0.046). These results are supported by Kalkunte et al. (2011) 
where IL-10 levels decreased in the third trimester compared to the first and second trimesters 
(Kalkunte et al., 2011). It is known that NK cells are reduced in the latter stage of pregnancy 
(Kane et al., 1996). In the EOPE group there was a concurrent increase in peripheral NK cells 
and IL-5 (p=0.036). Pre-eclampsia is associated with exaggerated inflammation which explains 
the increase in the cytotoxic peripheral NK cells in this study. IL-5 induces eosinophilia which 




4.7 Strengths and limitations of the study 
This novel study with a larger total sample population and pre-eclamptic groups compared to 
other studies (Mansouri et al., 2007; Pinheiro et al., 2013; Szarka et al., 2010; Kumar et al., 
2013; Jonsson, 2005), showed that levels of peripheral NK cells are higher in the pre-eclamptic 
group compared to the normotensive group. Also, our study revealed no significant difference in 
Th1 and Th2 maternal serum levels in HIV positive vs HIV negative, normotensive vs the pre-
eclamptic groups and in HIV associated pre-eclampsia. Unlike other studies the pre-eclamptic 
group in our study was stratified by gestational age (early and late onset) and HIV status 
(positive and uninfected). All HIV positive patients were on ARV treatment which may have 
played a role in restoring the maternal immune response. The duration of HIV patients on ARV 
treatment was unknown which may also be a limiting factor of this study. Also, the variability in 
maternal serum cytokine levels in pre-eclampsia may be attributed to sample type (serum or 
plasma) (Mansouri et al., 2007). Serum is recommended for bioassays however, cytokine levels 
may be affected during coagulation (Zhou et al., 2010). Patients were not sampled at different 
gestational ages up to delivery.  
 
4.8 Conclusion and future research 
To our knowledge, the quantification of peripheral NK cells as well as, Th1 and Th2 maternal 
serum cytokines in HIV associated pre-eclampsia is novel. Our study supports the hypothesis 
that the levels of peripheral NK cells are higher in the HIV positive pre-eclamptic group 
compared to the HIV positive normotensive group. Our study also suggests a neutralisation 
effect of Th1 and Th2 cytokines in HIV associated pre-eclampsia. Additionally, our study found 
that peripheral CD69 NK cells were higher in pre-eclamptic compared to the normotensive group 
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and GM-CSF was significantly different across each of the six study groups. Further studies may 
implicate CD69 and GM-CSF as possible biomarkers for early diagnosis of pre-eclampsia 
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APPENDIX V: LETTER OF STUDY INFORMATION AND CONSENT 
     STUDY NO. 
 




Nkosazane/Nkosikazi   
 
Sawubona, nginguNkosazane Anushka Ajith, umcwaningi kanye nesitshudeni se-PhD eNyuvesi 
YaKwaZulu-Natali.  
 
Senza ucwaningo lokuthola ukuthi yini ebangela umfutho wamandla egazi ophezulu kubantu besifazane 
abakhulelwe. Awunawo umfutho wamandla egazi ophezulu (i-hypertension). Ucwaningo yindlela nje 
yokuthola noma yokufunda impendulo embuzweni. Kulolu cwaningo, sizodinga ukuthi sithole ithisipuni 
legazi elivela kuwe. Ishubhu legazi elengeziwe lizothathwa kuwe ngesikhathi esifanayo nalesi 
okuthathwa ngaso elinye igazi elijwayelekile ukuze kuncishiswe nanoma yikuphi ukungaphatheki kahle 
ongahle ube nakho. Ukuthathwa kwegazi angeke kuphazamise ukukhulelwa kwakho noma umntwana 
wakho. Angeke siphazamise ukwelashwa kwakho. Odokotela esibhedlela bazokunika ukunakekelwa 
okujwayelekile.  
 
Sicela wazi ukuthi ungakwazi ukwala ukungena ocwaningweni, angeke uphathwe ngokuhlukile 
kwabanye. Wena azikho izindleko ozozithwala ngokubamba iqhaza ocwaningweni. Ucwaningo 
olwenziwa manje angeke lukusize kulokhu kukhulelwa kodwa luyokusiza kokunye esikhathini esizayo.  
 
Uma uvuma ukubamba iqhaza kulolu cwaningo, uzoba ngomunye weziguli eziningana ezibambe iqhaza 
kulolu cwaningo e-Prince Mshiyeni Memorial Hospital. Ulwazi maqondana nokubeletha kwakho 
luzotholakala eshadini lakho lokwelashwa bese lufakwa ekhasini lolwazi oluqoqiwe. Angeke ukhonjwe 
ngananoma iyiphi indlela njengoba umhlanganyeli ngamunye ezonikwa inombolo yocwaningo futhi 
nolwazi lwakho luyohlala lungaziwa ukuthi ngolukabani. Lonke ulwazi oluqoqiwe luzogcinwa 
kukhompiyutha (laptop) yomphenyi omkhulu ezovikelwa nge-password. Amakhophi abhalwe ephepheni 
azogcinwa ehhovisi lomphenyi elikhiywayo. Lonke ulwazi oluqoqiwe luzogcinwa isikhathi socwaningo 




Igazi lakho angeke ligcinelwe ukuhlaziywa okuqhubekayo noma ukukhishwa luyiswe kwamanye amazwe.  
Ngeke kwenziwe izivivinyo zofuzo egazini lakho. 
 
Lolu cwaningo luhlolwe ngokwezimilo futhi lwavunywa yi- UKZN Biomedical research Ethics Committee 
(inamba yemvume BE176/13). 
 
Uma kwenzeka uba nezinkinga noma okukukhazathayo/ imibuzo ungathintana nami kunombolo 
yeselula: 072 855 8414, Emsebenzini: 031 260 4750 nakwi-imeyili: ajith@ukzn.ac.za noma i-UKZN 
Biomedical Research Ethics Committee, imininingwane yokuthintana yile elandelayo:  
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Ucingo: 27 31 2604769 - Ifeksi: 27 31 2604609 




Mina _________________________ ngazisiwe ngocwaningo olunesihloko esithi “Iqhaza lamaseli abulala 
ngokwemvelo angabalulekile kuBantu Abamnyama abakhulelwe baseNingizimu Afrika abanomfutho 
wamandla egazi ophezulu abanezivikeli mzimba ezingaphenduli kahle kanye nabanomfutho wamandla 
egazi ojwayelekile” (“The role of peripheral Natural Killer cells in immunocompromised preeclamptic and 




Ngiyayiqonda inhloso kanye nezinqubo zocwaningo ezenzelwa ukuthola ukuthi yini ebangela umfutho 
wamandla egazi ophezulu kubantu besifazane abakhulelwe. Isipuni segazi sizothathwa kuwe ngesikhathi 
esifanayo nalesi okuthathwa ngaso elinye igazi elijwayelekile.  
 
Ngiye nganikezwa ithuba lokubuza imibuzo ngocwaningo futhi imibuzo yami iphendulwe ngendlela 
enganelisayo. 
 
Ngiyavuma ukuthi ukuhlanganyela kwami kulolu cwaningo kungukuzithandela kwami ngokuphelele futhi 
ngingayeka noma nini futhi lokhu ngeke kube nomthelela ekwelashweni kwami noma kokunye 
ukunakekelwa kwami engivame ukuba nelungelo lokukuthola. 
 
Ngazisiwe ngananoma yisiphi isinxephezelo esitholakalayo noma imithi yokwelashwa uma kwenzeka 
ukulimala kimi ngenxa yezinqubo eziphathelene nocwaningo. 
  
Uma nginanoma yimiphi eminye imibuzo/ukukhathazeka noma imibuzo ephathelene nocwaningo 
ngiyaqonda ukuthi ngingathinta umcwaningi kuselula: 072 855 8414, Emsebenzini: 031 260 4750 nakwi-
imeyili: ajith@ukzn.ac.za  
 
Uma nginemibuzo noma ukukhathazeka mayelana namalungelo ami njengomhlanganyeli, noma uma 
nginokukhathazeka mayelana nengxenye yalolu cwaningo noma ngabacwaningi ngingathintana ne-: 
  
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Ucingo: 27 31 2604769 - Ifeksi: 27 31 2604609 




____________________      ____________________ 
Isignesha yomhlanganyeli                          Usuku 
(ukuthathwa kwegazi) 
 
____________________      ____________________ 
Isignesha yomhlanganyeli                          Usuku 
(ukuvulwa kwamafayela ami esibhedlela) 
 
____________________   _____________________ 
Isignesha kafakazi                                       Usuku 
(Lapho kufanele khona)      
 
____________________   _____________________ 
Isignesha yomhumushi                               Usuku 
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APPENDIX VI: DATA COLLECTION TOOL 
THE ROLE OF PERIPHERAL NATURAL KILLER CELLS IN IMMUNOCOMPROMISED 
PREECLAMPTIC AND 
NORMOTENSIVE PREGNANT 
BLACK SOUTH AFRICANS 
 
IP/OP no:       Study no: 
 
Category (tick): (more than 1 category may require a tick) 
1. Pregnant Normotensive HIV +ve, CD4 < 350:       □ 
HAART         □ 
Triple regime (single tablet)       □ 
2. Pregnant Normotensive HIV +ve, CD4 > 350:        □ 
PMTCT (dual)        □ 
Triple regime (single tablet)       □ 




PLEASE CHECK EXCLUSION CRITERIA LIST   □ 
 
 
THE FOLLOWING BLOODS MUST BE TAKEN FOR THE PURPOSES OF THIS STUDY. 
PLEASE TICK IF THE BLOODS WERE TAKEN  
1. Sterile VAC 4ml K3EDTA lavender tube                         □ 
2. Sterile VAC 5ml serum gel SST red yellow tube                                    □                             
 
 
General hospital information 
Admission date  PMMH no  
 
Demographics 
Age (years)   
Area of Residence 
(tick) 
Rural Urban  
Cigarette smoking 
(y/n) 
 No. of 
cigarettes/day  
 
Alcohol  Quantity/day  
Recreational drugs 
(cocaine) 





Type of Treatment Yes No If Yes, no. of days 
Magnesium sulphate    
Aldomet    
Monoohydralazine    
Nifedipine    
Dihydralazine (nepresol)    
Labetalol    
Others    
 
Clinical data 
Parity P:         G: Weeks gestation on admission  
Reason for previous pregnancy loss (If any) 
Highest BP Systolic:                     Diastolic: 
Maternal weight  Maternal height  BMI   







Lab 24hr protein (if done) 
Creatinine clearance (if done) 
Full blood 
count 
Red cell count  White cell count  
Haemoglobin  Neutrophils  
Haematocrit  Lymphocytes  
Mean cell volume  Monocytes  
Mean cell Hb  Eosinophils  





Sodium  Urea  
Potassium  Creatinine  
Chloride  Anion gap  
CO2  Serum creatinine  
Liver function 
tests 
Total protein  Alkaline phos  
Albumin  AST  
Globulin  ALT  
Alb : Glob  LDH  
Total bilirubin    
 
Antenatal foetal investigations  
Type (tick ) Gestational age 
done 
 Note any abnormalities 
Sonar    
 








Weeks of gestation at time of  birth  
Date of birth Time of birth 











Combination of Maternal 




 Explain above if 
relevant 
 
Explain above if 
Relevant 
 





Method of Delivery 
(tick one) 
Normal vaginal Caesarean 
Spontaneous  Elective  





Severe pre-eclampsia Imminent eclampsia 
Abruptio-placentae  
Other (explain) 
Mother outcome Admitted to ICU Death 
 
Baby details at birth 
APGAR 1 min  5 min  






 Neonatal death 
(up to 28 days) 
   
Baby weight (kgs)  
Admission to NICU  
 
FOLLOW UP DATA PRIOR TO DISCHARGE FROM HOSPITAL 
Date:____________        Inpatient / Outpatient visit: _____________ 
 
Oedema (tick) ankle Up to knee Up to groin Generalised (facial) 
 
Any other observations/clinical data/information of relevance for mother: 






Baby weight: _______________ Maternal BP: ____________________ 
  
Feeding choice formula  Breast flash heating not fed TPN 







Morbidities in early NN period 
Resp Distress  
 











hypothermia,   





  eye, 
  umbilicus, 
 
  Suspected sepsis   





  Septicaemia  (positive BC), 
  meningitis (positive culture 
  NEC, 
  susp sepsis + low wcc and 
raised CRP (negative culture) 
 
All positive cultures = severe infections. CPAP and ventilalion = severe illness 
152 
 
Any other observations/clinical data/information of relevance for child: 






FOLLOW UP DATA AFTER DISCHARGE FROM HOSPITAL 
 
Date:____________        Inpatient / Outpatient visit: _____________ 
 
Oedema (tick) Ankle Up to knee Up to groin Generalised (facial) 
 
Baby weight: _______________ Maternal BP: ____________________ 
  







HIV status of baby 6 weeks 
post delivery 
HIV +ve (PCR) HIV –ve 
CD4+ cell count    
Baby NVP and AZT   (7 days or 28 days) 




Late morbidities   






Alive well  
Alive ill   - record morbidities as above 
 
Minor infections, HIV related infections, ROP 








THE ROLE OF PERIPHERAL NATURAL KILLER CELLS IN IMMUNOCOMPROMISED 
PREECLAMPTIC AND 
NORMOTENSIVE PREGNANT 
BLACK SOUTH AFRICANS 
 
IP/OP no:       Study no: 
 
Category (tick): (more than 1 category may require a tick) 
4. Preeclamptic HIV +ve, CD4 < 350:        □ 
                     HAART        □ 
                     Triple regime (single tablet)      □ 
5. Preeclamptic HIV +ve, CD4 > 350:        □ 
                     PMTCT (dual)       □ 
Triple regime (single tablet)      □ 
6. Preeclamptic HIV -ve:                  □ 
7. Onset preeclampsia before 33 wks        □ 




PLEASE CHECK EXCLUSION CRITERIA LIST   □ 
 
THE FOLLOWING BLOODS MUST BE TAKEN FOR THE PURPOSES OF THIS STUDY. 
PLEASE TICK IF THE BLOODS TAKEN  
3. Sterile VAC 4ml K3EDTA lavender tube                         □ 
4. Sterile VAC 5ml serum gel SST red yellow tube                                     □                             
 
 
General hospital information 
Admission date  PMMH no.  
 
Demographics 
Age (years)   
Area of Residence 
(tick) 
Rural Urban  
Cigarette smoking 
(y/n) 
 No. of 
cigarettes/day  
 
Alcohol  Quantity/day  
Recreational drugs 
(cocaine) 







Type of Treatment Yes No If Yes, no. of days 
Magnesium sulphate    
Aldomet    
Monoohydralazine    
Nifedipine    
Dihydralazine (nepresol)    
Labetalol    
Others    
 
Clinical data 
Parity P:         G: Weeks gestation on admission  
Reason for previous pregnancy loss (If any) 
Highest BP Systolic:                     Diastolic: 
Maternal weight  Maternal height  BMI   







Lab 24hr protein (if done) 
Creatinine clearance (if done) 
Full blood 
count 
Red cell count  White cell count  
Haemoglobin  Neutrophils  
Haematocrit  Lymphocytes  
Mean cell volume  Monocytes  
Mean cell Hb  Eosinophils  
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Platelets  Basophils  
Urea and 
electrolyte 
Sodium  Urea  
Potassium  Creatinine  
Chloride  Anion gap  
CO2  Serum creatinine  
Liver function 
tests 
Total protein  Alkaline phos  
Albumin  AST  
Globulin  ALT  
Alb : Glob  LDH  
Total bilirubin    
 
Antenatal foetal investigations  
Type (tick ) Gestational age 
done 
 Note any abnormalities 
Sonar    
 













Weeks of gestation at time of  birth  
Date of birth Time of birth 









Combination of Maternal 




 Explain above if 
relevant 
 
Explain above if 
Relevant 
 





Method of Delivery 
(tick one) 
Normal vaginal Caesarean 
Spontaneous  Elective  





Severe pre-eclampsia Imminent eclampsia 
Abruptio-placentae  
Other (explain) 
Mother outcome Admitted to ICU Death 
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Baby details at birth 
APGAR 1 min  5 min  




 Neonatal death 
(up to 28 days) 
   
Baby weight (kgs)  
Admission to NICU  
 
FOLLOW UP DATA PRIOR TO DISCHARGE FROM HOSPITAL 
Date:____________        Inpatient / Outpatient visit: _____________ 
 
Oedema (tick) ankle Up to knee Up to groin Generalised (facial) 
 
Any other observations/clinical data/information of relevance for mother: 






Baby weight: _______________ Maternal BP: ____________________ 
  
Feeding choice formula  Breast flash heating not fed TPN 




Morbidities in early NN period 
Resp Distress  
 











hypothermia,   





  eye, 
  umbilicus, 
 
  Suspected sepsis   





  Septicaemia  (positive BC), 
  meningitis (positive culture 
  NEC, 
  susp sepsis + low wcc and 
raised CRP (negative culture) 
 
All positive cultures = severe infections. CPAP and ventilalion = severe illness 
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Any other observations/clinical data/information of relevance for child: 






FOLLOW UP DATA AFTER DISCHARGE FROM HOSPITAL 
 
Date:____________        Inpatient / Outpatient visit: _____________ 
 
Oedema (tick) Ankle Up to knee Up to groin Generalised (facial) 
 
Baby weight: _______________ Maternal BP: ____________________ 
  







HIV status of baby 6 weeks 
post delivery 
HIV +ve (PCR) HIV –ve 
CD4+ cell count    
Baby NVP and AZT   (7 days or 28 days) 




Late morbidities   






Alive well  
Alive ill   - record morbidities as above 
 
Minor infections, HIV related infections, ROP 
and Audiology if small babies (<34 weeks), 
feeding choices 
ENND  
 
 
 
 
 
 
 
